The immune response to live vaccines against bovine anaplasmosis by Kenneil, Rachel & Pfister, Kurt
 
 
 
 
THE IMMUNE RESPONSE TO LIVE VACCINES  
AGAINST BOVINE ANAPLASMOSIS  
 
 
 
Thèse présentée à la faculté des Sciences 
Institut de Biologie 
Université de Neuchâtel 
Pour l’obtention du grade de docteur ès Sciences (Ph.D.) 
Par 
Rachel Kenneil 
 
 
 
Jury: 
Prof. Dr. Kurt Pfister, Directeur de thèse (Université de Neuchâtel, Switzerland) 
Prof. Dr. Lise Gern (Université de Neuchâtel, Switzerland) 
Prof. Dr. Patrick Guerin (Université de Neuchâtel, Switzerland) 
Prof. hon. Bruno Betschart (Université de Neuchâtel, Switzerland) 
Prof. Dr. Steffen Rehbein (Merial GmbH, Germany) 
 
Supervisor: Prof. Dr. Lygia Passos (Ludwig Maximilian University, Germany)  
 
 
Université de Neuchâtel 
2015 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Anaplasma marginale causes bovine anaplasmosis, a hemolytic disease which is a serious problem 
for the cattle industry in tropical and sub-tropical regions worldwide. A. centrale is a less 
pathogenic species which is closely related to A. marginale and used as a live vaccine against 
anaplasmosis. Unfortunately the A. centrale vaccine can only be produced from the blood of 
infected cattle, risking contamination with other pathogens. This project compared the A. centrale 
live vaccine with A. marginale UFMG1, a low pathogenicity Brazilian strain which has been 
proposed as a potentially safer live vaccine derived from cell culture. Calves were infected with 
UFMG1 or A. centrale, and then challenged with the pathogenic Israeli A. marginale Gonen strain.  
 
Previous infection with UFMG1 did not significantly reduce the severity of disease caused by 
challenge with the Gonen strain, whereas A. centrale infection did provide cross-protection against 
Gonen. In comparison to the antibody response to UFMG1 infection, the response to A. centrale 
infection had higher overall levels of IgG and showed higher cross-reactivity to Gonen strain 
antigen. The antibody response to A. centrale also had higher levels of IgG2, and showed more 
opsonophagocytic activity.  All of these characteristics correlated significantly with protection from 
disease upon challenge. Understanding how A. centrale infection stimulates this effective immune 
response would be a valuable direction for future vaccine research. 
 
Keywords: Anaplasma marginale, bovine anaplasmosis, immune response, opsonophagocytosis, 
live vaccines. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RÉSUMÉ 
Le rickettsies Anaplasma marginale provoque l'anaplasmose bovine, une maladie hémolytique qui 
est un grave problème pour l'industrie bovine dans les régions tropicales et subtropicales du monde 
entier. L’A. centrale est une espèce moins pathogène qui est étroitement liée à l’A. marginale et elle 
est utilisée comme vaccin vivant contre l'anaplasmose. Malheureusement, le vaccin A. centrale ne 
peut être produit qu’à partir du sang de bovins infectés, qui risquent d’être contaminés par d'autres 
agents pathogènes. Ce projet a comparé le vaccin vivant A. centrale avec A. marginale UFMG1, 
une souche brésilienne faiblement pathogène qui a été proposée comme un vaccin vivant issu de 
culture cellulaire et potentiellement plus sûr. Les veaux ont été infectés par UFMG1 ou A. centrale, 
puis inoculés avec la souche israélienne pathogène A. marginale Gonen. 
 
L’infection précédente avec UFMG1 n'a pas significativement réduit la sévérité de la maladie 
causée par la souche inoculée avec le Gonen, alors que l'infection par A. centrale a fournit une 
protection croisée contre le Gonen. Par rapport à la réaction des anticorps à l’infection UFMG1, la 
réaction à l'infection par A. centrale avait des niveaux globaux plus élevés d'IgG et a montré une 
réactivité croisée ultérieure à l'antigène de la souche Gonen. La réaction des anticorps à A. centrale 
avait également des niveaux plus élevés d'IgG2, et a montré une activité plus opsonophagocytaire. 
Toutes ces caractéristiques sont en corrélation significative avec la protection contre la maladie lors 
de l'épreuve. Comprendre comment l'infection par A. centrale stimule cette réponse immunitaire 
efficace serait une piste de recherche vaccinale prometteuse. 
 
Mots-clés : Anaplasma marginale, anaplasmose bovine, réponse immunitaire, opsonophagocytose, 
vaccins vivants. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1. WHAT IS A. MARGINALE? 
 
1.1.1. Classification 
Anaplasma marginale Theiler 1910 is a gram negative rickettsia and the causative agent of bovine 
anaplasmosis - a tick-transmitted hemolytic disease which causes serious economic problems to the 
cattle industry in tropical and sub-tropical areas worldwide (Kocan et al., 2010). At present, there is 
no safe and globally effective vaccine against bovine anaplasmosis, and vaccine development 
remains an area of active research.  
 
A. marginale belongs to the order Rickettsiales and the family Anaplasmataceae. This family 
consists of small, obligate intracellular bacteria, which are found within membrane-bound vacuoles 
in the cytoplasm of host cells (Dumler et al., 2001). Within the Anaplasmataceae family, the genus 
Anaplasma includes several species of particular economic interest: A. marginale, the type species 
for the genus; A. centrale, sometimes described as a sub-species of A. marginale (Shkap et al., 
2008); and A. phagocytophilum, which was formerly known by several different names - Ehrlichia 
phagocytophila, E. equi, or the causative agent of Human Granulocytic Ehrlichiosis (Dumler et al., 
2001).  
 
A. marginale was first isolated from cattle by Theiler (1910), who inaugurated the genus 
Anaplasma. He named the type species A. marginale after the 'marginal points' that the rickettsia 
formed in the infected erythrocytes. A. marginale infection has since been found in a wide range of 
wild and domestic ruminants, including cattle, bison, buffalo, wildebeest, deer and elk. However, 
reports of severe disease have exclusively been confined to cattle - experimental infection of other 
ruminant species produced only mild symptoms of anaplasmosis (Kuttler, 1984).  
 
Within the ruminant host, A. marginale primarily infects erythrocytes. Endothelial cell infection has 
also been detected in vivo (Carreño et al., 2007), but this does not appear to play an important role 
in the A. marginale life cycle (Wamsley et al., 2011). 
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1.1.2. Transmission 
A. marginale can be transmitted biologically by ticks, mechanically by biting flies or blood-
contaminated fomites, and transplacentally (Kocan et al., 2010). Around 20 different species of 
ticks have been implicated as vectors for biological transmission, with the most important genera 
being Dermacentor and Rhipicephalus. Across the majority of the tropical and sub-tropical range of 
A. marginale, Rhipicephalus (Boophilus) spp. are the most critical tick vectors, in particular R. (B). 
microplus and R. (B). annulatus. Since these species were eradicated from the United States in the 
first half of the 20th century, Dermacentor spp. particularly D. andersonii and D. variabilis, and D. 
albipictus, have taken over as the predominant biological vectors for A. marginale in the US. In 
Europe, multiple tick species have been proposed to play a role in anaplasmosis transmission (De la 
Fuente et al., 2005). Of the species suggested, D. reticulatus has the strongest evidence of being an 
important A. marginale vector in Europe: it is capable of experimental transmission of A.marginale 
(Zivkovic et al., 2007), A. marginale DNA has been isolated from D.reticulatus ticks during an 
anaplasmosis outbreak in Hungary (Hornok et al., 2012), and its range runs from France, through 
Eastern Europe to Central Asia, covering many of the areas in which A. marginale has been found 
(Karbowiak, 2014). 
 
Tick transmission can be transstadial or intrastadial; transovarial transmission has not been reported 
(Stich et al., 1989). When the tick feeds on infected cattle, the rickettsia are taken up as part of the 
blood meal, infect the gut cells of the tick, and then spread to other tissues. These tissues include the 
salivary glands, from where A. marginale can then be transmitted to new hosts during tick feeding 
(Ge et al., 1996).  
 
On a global scale, biological transmission by ticks is considered the most common route of A. 
marginale infection. But not all strains of A. marginale are tick-transmissable, and in some regions 
no tick vector species occur. Therefore, although it has lower transmission efficacy, mechanical 
transmission can also play an important role in the spread of A. marginale (Scoles et al., 2005). 
Mechanical transmission can be through various genera of biting flies (Tabanus, Stomoxys) or 
mosquitoes (Culex and Aedes), or through blood-contaminated fomites such as de-horning saws, 
ear-tagging devices, or castration instruments.  
 
Transplacental transmission has been measured at around 15 % by Potgieter and Van Rensburg 
(1987), and as such is also likely to contribute to A. marginale epidemiology. 
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1.1.3. Disease 
In the vertebrate host, A. marginale primarily infects erythrocytes. As part of the host response, 
these infected cells - along with considerable numbers of uninfected erythrocytes - are then 
destroyed by the reticuloendothelial system. Baker et al. (1961) measured up to a ten-fold increase 
in the rate of erythrocyte phagocytosis during acute A. marginale infection. This considerable loss 
of erythrocytes leads to anaemia and icterus, without hemoglobinemia or hemoglobinuria (Richey, 
1981). Other symptoms of bovine anaplasmosis include fever, lethargy, weight loss, lowered milk 
production, and abortion. It is often fatal in older cattle if they are not treated early (Kocan et al., 
2010). The severity of bovine anaplasmosis increases with age: calves under six months of age 
rarely become ill; between 6-12 months they usually develop mild disease, which is more acute at 
1-2 years old; finally, adults over two years old suffer acute and often fatal disease (Roby et al., 
1961; Aubry and Geale, 2011). The reason behind this increasing severity with age is as yet 
unknown. 
 
If cattle recover from acute disease, they usually remain persistently infected, often at 
microscopically undetectable levels (<107 rickettsia/ml). Throughout persistent infection, cattle 
show cyclical rises in rickettsemia (Eriks et al., 1993). These peaks in rickettsemia represent the 
generation of antigenic variants, which escape immune control and multiply rapidly, before they 
stimulate a variant-specific immune response that brings the infection under control again (French 
et al., 1999). Due to this consistent stimulation, persistently infected cattle maintain a strong 
immune response against A. marginale, and are protected from disease when subsequently 
challenged with the homologous A. marginale strain. Unfortunately they also act as reservoirs of 
infection for naïve cattle (Palmer et al., 1999). 
 
1.1.4. Economic Impact in Endemic Areas 
Bovine anaplasmosis has a serious economic impact on the cattle industry of endemic areas. Its 
effect is most serious in areas of endemic instability, where the transmission rate is too low to 
ensure that all cattle become infected as calves Aubrey and Geale, 2011). When cattle are first 
exposed to A. marginale as adults, they are much more likely to develop serious disease (Roby et 
al., 1961). 
  
Anaplasmosis causes direct losses through mortality, abortion, lowered weight of beef cattle and 
lowered milk production from dairy cattle. In addition, anaplasmosis frequently limits breed 
improvement  (Lombardo, 1976; Ocampo Espinoza et al., 2006). In Mexico, a highly endemic area, 
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anaplasmosis is estimated to cause up to a quarter of total deaths in national cattle improvement 
programmes (Rodriguez-Camarillo et al., 1999). When pedigree Bos taurus cattle are imported 
from temperate areas to endemic tropical or sub-tropical areas, the new cattle are likely to be 
extremely susceptible to A. marginale infection. This is due to both a lack of previous exposure, and 
to the greater susceptibility of B. taurus breeds (e.g. Holstein, Hereford) to tick-borne diseases in 
comparison to B. indicus cattle (Kocan et al., 2003).  
 
There have been relatively few studies quantifying the economic impact of bovine anaplasmosis. In 
the 1970s, McCallon (1973) estimated that the disease caused annual losses of over 300 million US 
dollars (USD) to the American cattle industry.  More recently, Tanzania was estimated to lose 47.3 
million USD solely due to the direct costs of bovine anaplasmosis (Kivaria, 2006).  
 
A. marginale is often considered in conjunction with the protozoan parasites Babesia bovis and B. 
bigemina, as all three are tick-borne pathogens which cause serious disease to cattle in tropical and 
sub-tropical regions of the world, and may often co-exist in the same animal. For example in Brazil, 
the three pathogens are referred to as one complex of disease, 'Tristeza Parasitária Bovina' 
(Gonçalves, 2000). This complex was estimated to cause a loss of 875 million USD to the cattle 
industry in South American countries (Brown, 1997). 
 
Global climate change is likely to increase the range of tick vector species, and so increase the 
regions affected by the pathogens they can transmit (Howden et al., 2010). As such, an ever-
increasing number of countries are working to develop a deeper understanding of tick-borne 
diseases such as anaplasmosis. 
 
1.2. IMMUNOLOGY 
Multiple parts of the immune system appear to play a role in the immune response to A. marginale. 
The serological response has been identified as an important part of protection after vaccination 
(reviewed by Palmer et al., 1999), and yet immune serum alone is not protective (Gale et al., 1992). 
Cell-mediated responses have also been shown to play a role in protection (Brown et al., 1998), but 
the T-cell response is inhibited by the pathogen to facilitate persistent infection (Han et al., 2010). 
Due to this complexity it remains an ongoing task to clarify which parts of the immune system can 
or should be targeted by A. marginale vaccines. 
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1.2.1. Serological Response 
High antibody levels, particularly of the subclass IgG2 (Brown et al., 1998; Barigye et al., 2004; 
Vega et al., 2007) or against major surface proteins (MSPs), (Tebele et al., 1991) have frequently 
been shown to correlate with protection. Antibodies can act through several routes: neutralization, 
opsonization, and complement-mediated bactericidal activity (Siegrist, 2012). 
 
Palmer and McGuire (1984) demonstrated that polyclonal immune sera could neutralize the 
infectivity of A. marginale for calves, and Palmer et al. (1987) showed the same neutralization 
effect with anti-MSP1a monoclonal antibody.  
 
Opsonophagocytosis, i.e. antibody-enhanced phagocytosis, has been proposed as an important 
mechanism to clear A. marginale infection (Palmer et al., 1999). An opsonin, which literally means 
'a flavoring', is any substance which makes whatever it binds to more likely to be 'eaten' by 
phagocytic cells (Murphy et al., 2012). The antibody classes IgM and IgG are the most effective 
opsonins. Within IgG, different IgG subclasses have different levels of efficacy in opsonization; in 
cattle, the IgG2 subclass is the best opsonin (McGuire and Musoke, 1981). 
 
In the presence of immune serum, antigen-specific antibodies coat the surface of bacteria, allowing 
the C1 complement protein to bind to the antibody-antigen complex. Once bound, C1 is activated 
and triggers the complement cascade, binding and activating a sequence of complement proteins 
including the opsonins C3 and C4. Phagocytic cells will then bind greatly enhanced numbers of 
these opsonized or 'flavored' bacteria, through their receptors for C3 and C4 complement proteins, 
and for the Fc portion of antibody (Murphy et al., 2012). In the absence of any antibody, bacteria 
can still be recognized by phagocytic cells via pathogen recognition receptors (PRRs) which bind to 
common pathogen components such as lipopolysaccharide (LPS). The complement protein C3 also 
binds at low levels directly to the bacterial surface, leading to its activation and recognition by the 
C3 receptor on the phagocyte (Murphy et al., 2012). An overview of the opsonophagocytosis of 
bacteria is shown in Figure 1. 
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Figure 1: An overview of opsonophagocytosis of bacteria by immune sera.  
(A) Without immune sera, only a small amount of complement protein will bind to bacteria.  
(B) When immune serum is added, antibodies bind to epitopes on the surface of the bacteria. High 
amounts of complement proteins then bind to the antibody-antigen complex that has formed on the 
bacteria.  
(C) Phagocytic cells recognize opsonized bacteria through the cell's receptors for antibody (FcR) 
and for complement proteins (C3R, C4R).  
(D) The binding of opsonized bacteria to these receptors triggers the cell to internalize the bacteria 
in a membrane vesicle (the phagosome). The phagosome then fuses with other vesicles called 
lysosomes, which contain a range of antimicrobial components, and the bacteria are broken down 
by toxic reactive oxygen species and nitrogen oxides, acidification, proteolytic enzymes, and 
antimicrobial peptides. 
 
Cantor et al. (1993) demonstrated that sera from MSP1-immunized cattle could significantly 
enhance in vitro opsonization of A. marginale. Melendez (2005) showed that immune sera from 
naturally infected cattle enhanced phagocytosis of both infected and uninfected erythrocytes, 
suggesting that opsonophagocytosis could be a double-edged sword: both limiting the spread of A. 
marginale, and contributing to the severe anemia that characterizes the disease.  
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Serum bactericidal activity against A. marginale has not yet been assessed.  
 
Despite the demonstrated activity of antibodies against A. marginale, immune serum alone is not 
sufficient to prevent disease. In a classic passive protection experiment, Gale et al. (1992) showed 
that transfer of serum from hyper-immune to naïve calves was insufficient to protect the latter from 
disease. In addition, immune suppression by splenectomy or drugs leads persistently infected 
asymptomatic cattle to suffer a relapse in symptoms within 1-2 weeks – this relapse occurs before 
circulating IgG levels show a significant fall (Jones et al., 1968; Kuttler and Adams, 1977). 
 
1.2.2. Cell-mediated Immune Response  
There is ample evidence that cell-mediated immunity also plays a role in the host response to A. 
marginale. In early experiments, protection against bovine anaplasmosis correlated with inhibition 
of leukocyte migration (Buening, 1976) and development of cutaneous hypersensitivity (Carson et 
al., 1976), indicating an association with T-cell responsiveness and macrophage activation, 
respectively. Brown et al. (1998) demonstrated that after cattle were vaccinated with outer 
membrane proteins, their protection from challenge correlated with their level of CD4+ T-cell 
proliferation, and with functions associated with CD4+ T-cells, namely the production of IFNγ and 
IgG2.  
 
These findings led to the current paradigm for a protective immune response to vaccination, 
proposed by Palmer et al. (1999). This model centers around antigen-specific CD4+ T-cells, and 
their production of IFNγ, which activates macrophages and stimulates B-cells to produce more 
IgG2. Antigen-specific IgG2 opsonises the rickettsia, increasing their uptake by the activated 
macrophages and leading to control of the infection.  
 
This model has been challenged by more recent research, which suggests that CD4+ T-cells do not 
appear to be essential to protection from anaplasmosis. When calves were thymectomized 
(removing their ability to develop new T-cells), and then had their existing CD4+ T-cells depleted, 
they were still able to control A. marginale infection. They showed no significant difference in 
disease severity compared to untreated calves (Valdez et al., 2002). There is a caveat to this study in 
that CD4+ T-cell depletion was not absolute (as this is very difficult to achieve).  
 
Interestingly, a natural depletion of T-cells during infection appears to be a persistence strategy of A. 
marginale (Han et al, 2010). Vaccination with A. marginale surface proteins MSP2 (Abbott et al., 
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2005) or MSP1a (Han et al., 2008) induced high levels of antigen-specific CD4+ T-cells; these high 
levels rapidly fell after the cattle were infected with A. marginale. Later in infection only low and 
sporadic T-cell responses were seen. This phenomenon was not the general immunosuppression 
seen after A. phagocytophilum infection. The T-cell reduction was confined to those cells which 
responded to A. marginale antigen, with the level of CD4+ T-cells specific for a control antigen 
remaining high after A. marginale infection (Han et al., 2010). 
 
The inhibition of a T-cell response to A. marginale is very likely to contribute to its long-term 
persistence in infected cattle. However, the inhibition may also benefit the host. Continuous CD4+ 
T-cell activity in response to the cyclically high bacterial loads seen in persistent A. marginale 
infection would likely lead to systemic inflammation, damaging the host (Han et al., 2010). In fact, 
down-regulation of T-cell responses is frequently seen in long-term persistent infections where 
antigen loads remain high (Jenson et al., 2002; Xu et al., 2002).  
 
The majority of studies on the T-cell response to A. marginale have focused on alpha-beta T-cells. 
These are the most abundant T-cell type, encompassing CD4+ and CD8+ T-cells, and a range of 
regulatory T-cells. Another type of T-cell which may also play a role in the response to A. marginale 
infection is the gamma-delta T-cell. Gamma-delta T-cells are particularly abundant in ruminants, 
and are at their highest levels in younger animals – the age at which anaplasmosis causes the 
mildest symptoms (Hein and MacKay, 1991; Roby et al., 1961). Gamma-delta T-cell clones specific 
for A. marginale MSP2 have been shown to respond to antigen by proliferating, producing IFNγ, 
and expressing a range of chemokines which recruit inflammatory cells (Lahmers et al., 2005; 
2006). However, the dynamics of gamma-delta T-cells during infection with A. marginale have not 
yet been reported. 
 
Much of the nature of the T-cell response to A. marginale remains to be clarified - in particular, 
whether the effects of T-cell deletion during A. marginale infection prevent the T-cell response from 
having any protective effect against bovine anaplasmosis. 
 
 
 
 
 
 
9 
1.3. CONTROL MEASURES AGAINST A. MARGINALE 
Control measures vary in different areas, according to their expense, practicality, and the 
preferences of the region. Controlling arthropods with acaricide treatment is useful for limiting the 
spread of various vector-borne diseases, including anaplasmosis. But as A. marginale can also be 
transmitted mechanically and transplacentally, acaracides cannot totally eliminate the spread of this 
rickettsia. In addition, regular use of acaricides is expensive and can hasten the development of 
resistance (Kocan et al., 2010). 
 
1.3.1. Chemotherapy 
Tetracycline antibiotics are by far the predominant treatment for bovine anaplasmosis. Trials of 
imidocarb (Roby et al., 1972) and enrofloxacin (Facury-Filho et al., 2012) have also shown good 
results, but they are not commonly used (Coetzee et al., 2006). Repeated doses of tetracycline can 
eliminate persistent A. marginale infections, although complete elimination is not always achieved 
(Swift and Thomas, 1983).  
 
Tetracycline is most effective in the earlier stages of the disease (Kuttler et al., 1980), so it can be 
difficult to catch the disease early enough in range cattle (Kocan et al., 2010). Therefore it is 
sometimes used prophylactically, particularly in the US (Kocan et al., 2010). Such frequent use of 
antibiotics has the potential to cause selection of resistant strains, but to date this has not been 
reported as a problem. The withholding period in antibiotic-treated cattle before they can be used 
for meat or milk can be an issue for farmers, particularly with long-lasting oxytetracycline 
preparations (Lew-Taylor, 2012). 
 
In some regions, tetracyclines are used for the 'infection-treatment' control method: cattle are 
inoculated with A. marginale-infected erythrocytes, and then treated early in the patent phase of 
disease by low doses of tetracycline drugs. The aim is the development of persistent infection 
without acute disease. As the animals have the opportunity to develop an immune response, they 
will subsequently be immune to challenge with homologous strains. However, the infection-
treatment method requires careful monitoring to ensure acute disease does not develop, and so can 
be unsuitable for large herds of cattle (Kocan et al. 2003). 
 
1.3.2. Vaccination 
Despite the effectiveness of antibiotic treatment, demand for a vaccine is still high (Spath et al., 
1990; Kocan et al., 2010). Existing vaccines can be effective control methods for bovine 
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anaplasmosis, but developing improved vaccines which are safer and globally effective has long 
been an objective of the cattle industry (Palmer et al., 1989).  
 
No vaccines tested to date reliably induce sterile immunity. Instead, when vaccinated cattle are 
challenged, they develop persistent infection without acute disease, and so can still act as reservoirs 
of infection for naïve cattle (Bock and deVos, 2001). Various types of vaccine against bovine 
anaplasmosis have been studied. Killed and live vaccines have been frequently used in the field; 
recombinant protein, outer membrane, and DNA vaccines have so far been confined to small 
research trials (Kocan et al., 2010). 
 
1.3.2.1 Killed vaccines 
The commercial vaccine 'Anaplaz' consisted of killed A. marginale derived from the blood of 
infected cattle (Fort Dodge Laboratories, Fort Dodge, Iowa). 'Anaplaz' was marketed for several 
decades in the US before being withdrawn due to company restructuring (Kocan et al., 2003). 
Killed vaccines have several advantages over live vaccines: less chance of contamination with other 
pathogens, greater ease of storage, and low post-inoculation reactions. However, they offer limited 
cross-protection against strains from different regions (Kuttler et al., 1984), and require yearly 
boosters since they only induce short-term immunity (Brock et al., 1965). Moreover, expensive 
purification procedures are needed to remove erythrocyte debris (McCorkle-Shirley et al., 1985). If 
the rickettsia are insufficiently purified from erythrocyte stroma, repeated vaccination may 
stimulate isoantibodies against erythrocyte proteins. Calves ingesting colostrum from cows with 
high isoantibody titres may then develop hemolytic anemia (Dennis et al., 1970). The occurrence of 
this problem was reduced by improved purification protocols (Hart et al., 1990), and the 
introduction of guidelines not to vaccinate cows in the later stages of pregnancy (Luther et al., 
1989). 
 
1.3.2.2. Outer Membranes, Recombinant Proteins, and DNA Vaccines 
Outer membrane proteins (OMPs) are common vaccine targets as they will be exposed to the host's 
immune system during infection (Grandi, 2010). The A. marginale proteins that have been 
considered as vaccine candidates are therefore OMPs, with the majority of research being focused 
on the most highly expressed OMPs. These are the most abundant and immunogenic proteins on the 
surface of A. marginale, and are known collectively as the Major Surface Proteins (MSPs), MSP1a, 
MSP1b, MSP2, MSP3, MSP4, and MSP5 (Agnes et al., 2011).  
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MSP1a and MSP1b form the MSP1 complex, which is involved in cell entry. MSP1a is necessary 
and sufficient for attachment to both erythrocytes and tick cells (de la Fuente et al., 2003), while 
MSP1b only plays a role in attachment to erythrocytes (de la Fuente et al., 2001). MSP2 and MSP3 
are both transcribed from large multi-gene families. They vary considerably between isolates 
(Alleman et al., 1997; Palmer et al., 1994), and even express variant sequences over the course of 
persistent infection (Brayton et al., 2003; Barbet et al., 2001; French et al., 1999). MSP4 and MSP5 
are both encoded by single-copy genes, and are highly conserved. As such they are useful for 
phylogenetic analysis (de la Fuente et al., 2002b) and diagnostics, with MSP5 used for a 
commercial diagnostic ELISA (de Eschaide et al., 1998). 
 
Outer membrane protein vaccines 
Outer membrane protein (OMP) vaccines are a complex mix of proteins of varying 
immunogenicity. At least 25 different antigenic OMPs have been identified (Lopez et al., 2005; Noh 
et al., 2008). Several studies have demonstrated that OMP-based vaccines can induce protection 
against homologous challenge (Tebele et al., 1991; Brown et al., 1998; Noh et al., 2008), but 
Palmer et al. (1994b) found they did not significantly reduce disease symptoms after heterologous 
challenge. In addition, OMP vaccines are expensive to prepare and difficult to standardize (Noh et 
al., 2013). 
 
Recombinant protein vaccines 
Recombinant protein vaccines are often less protective than OMP vaccines. This is perhaps 
unsurprising, as they usually consist of a single protein rather than the complex mix of immunogens 
seen in OMP vaccines (Palmer and McElwain, 1995). 
 
The majority of recombinant protein vaccines have used MSPs. Despite good results with native 
protein (Palmer et al., 1989), recombinant MSP1 (in the form of the MSP1a/MSP1b complex) has 
had mixed results, with some studies finding protection against homologous strains (Camacho-Nuez 
et al., 2000), and others not (Palmer and McElwain, 1995). Although MSP2 and MSP3 are highly 
immunogenic (Palmer et al., 1999), their high variability makes them unsuitable targets for a widely 
protective vaccine (Albarrak et al., 2012). There has been very limited study of recombinant MSP4 
and MSP5; the former induced protection against homologous challenge, the latter not (A.F. Barbet, 
unpublished data, cited in Palmer and McElwain, 1995). 
 
The high variability of the most abundant OMPs (the immunodominant MSP2 and MSP3) has led 
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some groups to focus on sub-dominant OMP antigens. Candidate sub-dominant antigens are those 
which are highly conserved between strains and over the course of infection, and are still 
immunogenic despite being less abundant. Multiple antigens have been identified which fit these 
requirements (Lopez et al., 2005; Noh et al., 2008; Sutten et al., 2010; Agnes et al., 2011), but so 
far only one, AM779, has been tested as a recombinant protein vaccine. It was immunogenic but not 
protective, raising the possibility that multiple sub-dominant antigens may have to be combined 
create an effective recombinant protein vaccine (Albarrak et al., 2012).  
 
DNA vaccines 
DNA vaccines have been tested in mice (Kano et al., 2008) and cattle (Arulkanthan et al., 1999; 
Mwangi et al., 2007). Interestingly, Arulkanthan et al. (1999) found that the bovine antibody 
response to a MSP1a DNA vaccine was largely restricted to IgG1, which is not associated with 
protection (Brown et al., 1998). However, an MSP1b-based DNA vaccine has been shown to induce 
partial protection from disease (de Andrade et al., 2006).  
 
1.3.2.3. Live vaccines 
Live vaccines have been used against bovine anaplasmosis for over a century, beginning shortly 
after A. marginale was first identified (Theiler, 1912). Today live vaccines are perhaps still the most 
widely used type (Kocan et al., 2003). As live vaccines lead to a persistent infection in vaccinated 
cattle, they provide them with lifelong protection against severe disease. They produce a stronger 
immune response than killed vaccines, with the generation of antigenic variants during persistent 
infection leading to a broader immune response (Palmer et al. 1999).  
 
The practise of deliberately establishing a persistent infection with a less pathogenic strain in order 
to create immunity against a more severe infection is known as premunition or premunisation 
(Kuttler et al., 1984b). Vaccines for premunisation are customarily produced from the blood of 
splenectomized calves, which develop high levels of rickettsemia after infection (Kocan et al., 
2003). The infected blood must then be kept chilled (for use within a week) or cryopreserved (for 
longer term storage, and quality control) (McElwain, 2008). Natural variation can be a problem 
with live vaccines: it can lead to variants which either cause unexpectedly serious disease, or do not 
maintain sufficient infectivity for successful premunisation (Bock et al., 2003).  
 
Attenuated A. marginale 
Several approaches have been used to attenuate pathogenic A. marginale to make them suitable for 
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use as a live vaccine: passage through sheep (Ristic et al., 1968), passage through deer (Kuttler and 
Zaugg, 1988), or 60Co irradiation (Sharma and Bansal, 1986). The most successful attenuated 
vaccine was produced in sheep by Ristic et al. (1968). It induced protection with limited side effects 
in several trials (Welter and Ristic, 1969; Osorno et al., 1975; Ristic and Carson, 1977). However, 
other investigators found severe post-vaccination reactions (Anziani et al., 1981; Henry et al., 
1983).  
 
Naturally low pathogenic A. marginale strains 
Low pathogenic strains of A. marginale cause mild or no disease without needing deliberate 
attenuation. Several low pathogenic strains have been tested as live vaccines: the Dawn strain from 
Australia (Bock et al. 2003; Carter et al., 2006); the Yucatan strain from Mexico (Rodriguez-
Camarillo et al., 2008); and the UFMG1 strain from Brazil (Bastos et al., 2010). A low 
pathogenicity field isolate from Colombia has also been tested as part of a combination babesiosis-
anaplasmosis live vaccine (Benavides et al., 2000).  
 
All these strains, with the exception of the combination vaccine, induced good protection against 
homologous strains, and against heterologous A. marginale strains from the same geographic area. 
However, none have yet successfully progressed into wider use outside their country of origin.  
 
Anaplasma centrale 
Anaplasma centrale is a low pathogenic species closely related to A. marginale, which was first 
identified in South Africa by Sir Arnold Theiler, shortly after he isolated A. marginale (Theiler, 
1912). As only a few, quite variable, A. centrale isolates have been sequenced, it is difficult to 
determine whether A.centrale should be identified as a variant of A.marginale, a sub-species, or a 
separate species. 16S rRNA analysis based on a Japanese A. centrale isolate classified it as a distinct 
species (Inokuma et al., 2001), but analysis of two South African A.centrale (including the vaccine 
strain, A. centrale Theiler, 1911) by 16S rRNA (Dumler et al., 2001) and GroEL sequences (Lew et 
al., 2003) classified A. centrale as an A. marginale sub-species.  
 
As the name suggests, A. centrale inclusions are generally seen in the centre of erythrocytes, as 
opposed to the 'marginal points' of A. marginale (Theiler, 1912). Theiler determined that animals 
infected with A. centrale only showed mild disease or were asymptomatic, and were subsequently 
protected from challenge with pathogenic A. marginale. In the decades after this discovery, A. 
centrale was exported to various countries to be used as a live vaccine against bovine anaplasmosis 
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– not only to other countries in Africa, but further afield to Israel, Australia, and parts of South 
America (Shkap et al., 2008; Bock and de Vos, 2001; De Wall, 2000; Melendez et al., 2003).  
 
In all these regions, A.centrale is generally very effective at protecting cattle against bovine 
anaplasmosis (Bock and de Vos, 2001). Nevertheless there have been some reports of vaccine 
failure, particularly against highly pathogenic A. marginale strains (Wilson et al., 1980; Payne et 
al., 1990; Turton et al., 1998; Brizuela et al., 1998; Bock and de Vos, 2001), and A. centrale itself 
has been reported to cause disease if administered to adult cattle (Pipano, 1976; Potgieter 1979; 
Bigalke 1980; Pipano et al., 1985). 
 
As with all the live vaccines that have been used in the field so far, A. centrale is produced from the 
blood of infected splenectomized calves (Pipano, 1995). Blood-derived vaccines risk accidental 
transmission of other blood-borne pathogens. For example when one calf used for vaccine 
production became accidentally infected with bovine leucosis virus, over 10,000 A. centrale 
vaccines doses were contaminated (Rogers et al., 1988).  
 
1.3.2.4. Tick-cell culture as a source of vaccines 
Tick cell culture has been proposed as a safer and more easily standardized source of live vaccines. 
A. centrale has never successfully been cultivated in vitro, but multiple A. marginale strains have 
been propagated in tick cell lines (Passos, 2012). In vitro-derived A. marginale remain infective for 
cattle and ticks (Munderloh et al., 1996), and keep the same antigenic composition through repeated 
passages in tick cell culture (Barbet et al., 1999). Tick cell-derived A. marginale have been shown 
to be immunogenic when used as a killed (Kocan et al., 2001; de la Fuente et al., 2002) or live 
inoculum (Bastos et al., 2010; Hammac et al., 2013). When compared with blood-derived A. 
marginale of the same strain, they induced similar levels of protection (de la Fuente et al., 2002; 
Bastos et al., 2010).   
 
Tick cell culture-derived A. marginale would be more easily standardized and safer than blood-
derived vaccines, with a lower risk of contamination by other pathogens, and no potential auto-
immune complications from contaminating erythrocyte proteins. Therefore tick cell culture-derived 
A. marginale are a focus of current research into new live vaccines. 
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1.4. THESIS STRUCTURE 
The aim of this project was to investigate the immune response to live vaccines against bovine 
anaplasmosis. A. centrale, the current 'gold-standard' live vaccine, was compared with a naturally 
low pathogenic Brazilian A. marginale strain (UFMG1), which has been successfully established in 
cell culture and so has the potential of being a cell culture-derived live vaccine. 
 
 
Chapter 2 describes a trial comparing the effectiveness of A. centrale and UFMG1 in protecting 
calves against challenge with a pathogenic Israeli strain, A. marginale Gonen.  
 
Chapter 3 investigates the serological response induced by A. centrale and A. marginale UFMG1.  
 
Chapter 4 investigates the cell-mediated response to A. centrale and A. marginale UFMG1 – 
namely PBMC proliferation and IFNγ production.  
 
Chapter 5 describes the development of an in vitro assay for serum opsonophagocytosis activity 
(OPA) against A. marginale, based on flow cytometric measurement of the oxidative burst response 
to phagocytosis. OPA has been suggested as a correlate of protection for bovine anaplasmosis, but 
this has never been experimentally confirmed.  
 
 
Chapters 2 and 3 are partially based on: 
 
R.Kenneil, V. Shkap, B.Leibovich, E. Zweygarth, K. Pfister, M.F. Ribeiro, L.M.Passos (2013). 
Cross-protection between geographically distinct Anaplasma marginale isolates appears to be 
constrained by limited antibody responses. Journal of Transboundary and Emerging Diseases 60 
Suppl.2: 97-104. 
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CHAPTER 2: CLINICAL RESULTS OF LIVE VACCINE TRIAL OF 
A. MARGINALE UFMG1 AND A. CENTRALE 
 
2.1. INTRODUCTION 
2.1.1. A. centrale as a live vaccine against Anaplasma marginale 
Live vaccination with Anaplasma centrale is the most widely used method to prevent bovine 
anaplasmosis (Kocan et al., 2003). It has been used as a live vaccine from 1912, when it was first 
identified by Sir Arnold Theiler (Theiler, 1912). It is currently used throughout Israel, Australia, and 
parts of Africa and South America (Shkap et al., 2008; Bock and de Vos, 2001; De Wall, 2000; 
Melendez et al., 2003). It is not licensed for use in the EU, the USA and Mexico (Kocan et al., 
2003). Cattle infected with A. centrale develop a persistent infection with mild or no disease. When 
vaccinated cattle are subsequently exposed to pathogenic A. marginale, they still become infected 
but are protected from serious illness (Shkap et al., 2008).  
 
Although vaccination with A. centrale is generally very effective against bovine anaplasmosis, there 
have been reports of severe side effects in older cattle (Pipano et al., 1985), and of vaccine failure, 
especially against high pathogenic A. marginale strains (Turton et al., 1998, Brizuela et al., 1998, 
Guglielmone and Vanzini, 1999; Payne et al., 1990; Bock & de Vos, 2001). An additional problem 
is that the vaccine is produced from the blood of infected splenectomized calves (Pipano, 1995), 
which risks accidental transmission of other blood-borne pathogens. Furthermore, using calves for 
vaccine production is laborious, expensive, and should be replaced wherever practical with more 
ethical alternatives.  
 
2.1.2. Cell culture-derived A. marginale UFMG1 as a potential vaccine 
Unfortunately, despite many attempts A. centrale has never been cultivated in vitro. In contrast, 
several A. marginale strains have been successfully established in tick cell culture (as reviewed by 
Bell-Sakyi et al., 2007; Passos, 2012). Vaccines derived from cell culture would have improved 
safety and reproducibility over those produced from blood. Initial studies with inactivated cell 
culture-derived A. marginale have shown that they remain immunogenic and can induce protection 
against homologous strain challenge (Kocan et al., 2001; de la Fuente et al., 2002b). Cell culture-
derived A. marginale also remain infective for cattle and ticks (Munderloh et al., 1996), and so can 
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be used as live vaccines. Bastos et al. (2010) demonstrated that infection with UFMG1, a naturally 
low pathogenic Brazilian A. marginale strain, protected cattle from disease on subsequent challenge 
with UFMG2, a heterologous high pathogenic Brazilian strain. Blood- or cell culture-derived 
UFMG1 induced statistically similar levels of protection. Bastos et al. (2010) therefore proposed 
that UFMG1 could be a potential cell culture-derived live vaccine against bovine anaplasmosis. 
 
UFMG1 is a strain with an inclusion appendage which was first isolated from an infected calf in the 
Minas Gerais province of Brazil by Ribeiro et al. (1997). It is not transmissible by Rhipicephalus 
(Boophilus) microplus, the main tick vector of A. marginale in Brazil (Gonçalves-Ruiz et al., 2005). 
However, it has been successfully cultivated in vitro in BME26, an R. (B). microplus-derived cell 
line (Esteves et al., 2009), and in IDE8, an Ixodes scapularis-derived cell line (Bastos et al., 2009), 
despite I. scapularis not being a natural A. marginale vector. When UFMG1 was tested as an 
inactivated vaccine by Lasmar et al. (2012), it did induce seroconversion but did not achieve the 
protection against the high pathogenic strain UFMG2 that was seen by Bastos et al. (2010). This 
echoes previous results that live vaccines are more efficacious than killed (reviewed by Kocan et 
al., 2003). 
 
2.1.3. The problem of cross-protection between strains 
 
Bastos et al. (2010) demonstrated that UFMG1 infection could protect cattle against disease caused 
by UFMG2, a heterologous strain originating from the same country. However, one of the main 
problems with controlling A. marginale is the high variability of strains from different regions. Over 
two hundred different strains have been reported across the global range of A. marginale (Cabezas-
Cruz et al., 2013), and even within one herd there may be multiple strains circulating (Alamzan et 
al., 2008; Pohl et al., 2013). Since there is often limited cross protection between heterologous 
strains, this high level of diversity is a major barrier to developing an effective global vaccine 
against bovine anaplasmosis. A good vaccine in one region may only offer limited protection in 
another (Palmer et al., 1994; Ocampo Espinoza et al., 2006). 
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2.1.4. Protection with or without infection-exclusion 
‘Infection-exclusion’ is a theory that persistent infection with one A. marginale strain excludes 
secondary infection with a challenge strain. This theory was proposed by de la Fuente et al. 
(2002a), as a possible explanation for the action of live anaplasmosis vaccines. Infection-exclusion 
was demonstrated between two strains in vivo in cattle and ticks, and in vitro in bovine erythrocytes 
and tick cell culture (de la Fuente et al., 2002a; 2003). However, infection-exclusion does not occur 
with the A. centrale vaccine (Shkap et al., 2008), or with all combinations of A. marginale strains 
(Palmer et al., 2004; Bastos et al., 2010). Rodriguez et al. (2005) determined that the deciding 
factor was the msp2 pseudogene repertoire of the strains tested. When the two strains had 
overlapping msp2 repertoires, infection-exclusion was seen; in contrast, strains with distinct msp2 
repertoires developed co-infections. Live anaplasmosis vaccines can sometimes cause infection 
exclusion, but since msp2 is highly variable (Futse et al., 2008) this means of protection will only 
work against a limited number of strains. The most important aspect of any vaccine proposed for 
widespread use is its ability to induce protection without infection exclusion.  
 
UFMG1 protected cattle against UFMG2 without infection-exclusion occuring (Bastos et al., 2010). 
Interestingly, when co-infection with UFMG1 and UFMG2 developed after challenge, a new 
UFMG2 msp1a tandem repeat variant was found in several cattle. Co-infection has previously been 
implicated as a driver for msp2 diversity (Futse et al., 2008). The msp1a gene is also under positive 
selection pressure (Cabezas-Cruz et al., 2013). Therefore it is possible that co-infections, whether 
natural or deliberate, may also be a selective pressure driving the diversity of msp1a sequences.  
 
This could present an issue for research into the epidemiology of A. marginale, as at present the 
most common way of differentiating between strains is through their msp1a sequence – namely by 
sequencing the N-terminal tandem repeat region of msp1a, and then determining how closely the  
amino acid sequence of the repeats match to previously published strains*. This is used because the 
MSP1a tandem repeat region been sequenced for the majority of published strains, and sufficient 
variation is seen between different A. marginale isolates that it can serve as a useful way of 
estimating the A. marginale variability in a population of infected cattle, and can be used to track 
strains for epidemiological studies**. Within one isolate, several studies** have shown that MSP1a 
tandem repeats remains unchanged through A. marginale infection in cattle or ticks, and through  
transmission between hosts. If co-infection with two or more A. marginale strains provides selective 
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pressure which leads to changes in MSP1a repeat sequences, this would make consistent 
identification of different strains much more unreliable. 
 
 
2.1.5. Aims of the vaccine trial 
Bastos et al. (2010) has already shown that UFMG1 can protect cattle against a heterologous 
Brazilian strain. The next step in characterizing the potential of UFMG1 as a vaccine is to 
investigate whether it can also induce protection against non-Brazilian A. marginale strains. A 
broadly cross-reactive response would imply it could potentially be useful in affected areas across 
the world. Therefore in this study UFMG1 was tested for its ability to protect cattle against a 
pathogenic Israeli A. marginale strain. The effectiveness of UFMG1 was compared to the current 
standard live vaccine, A. centrale. After challenge, cattle were tracked for establishment of co-
infections (i.e. protection without infection exclusion), and for changes to the msp1a sequence.
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2.2. MATERIALS AND METHODS 
2.2.1. A. marginale and A. centrale strains 
A. marginale UFMG1 (msp1α sequence GenBank EU676176), was originally isolated from a 
naturally infected calf in Minas Gerais State, Brazil, as described by Ribeiro et al. (1997). At the 
time of the trial UFMG1 had been continuously maintained in IDE8 tick cells for approximately 5 
years at the Universidade Federal de Minas Gerais, Brazil, and then the Ludwig-Maximilians-
Universität, Munich, Germany, using standard culture methods described by Bastos et al. (2010).  
 
The A. centrale vaccine strain (full genome sequence GenBank CP001759) used in the trial is 
routinely used as a live vaccine in Israel (Shkap et al., 2008). It has been maintained through 
inoculation of splenectomized calves at the Kimron Veterinary Institute, Bet Dagan, Israel. 
  
A. marginale Gonen (hereafter referred to as Gonen) originated from a field case at the Gonen farm 
in the north of Israel. It was determined to have one of the most common msp1a genotypes in Israel 
at the time the strain was isolated (Molad et al., 2009). Blood collected from the original infected 
cow (msp1α sequence GenBank EU678755) was subcutaneously inoculated into a splenectomized 
calf, resulting in minimum hematocrit of 9 % and maximum rickettsemia of 55 % before the calf 
was treated with oxytetracycline to prevent death (V. Shkap, written communication). Blood taken 
from the calf before antibiotic treatment was used to infect another splenectomized calf, which 
showed similar symptoms. Blood cryostabilate prepared from the latter calf was used in this trial. 
 
To obtain sufficient infective material for cattle inoculation, A. centrale and A. marginale UFMG1 
and Gonen were first individually subcutaneously inoculated into 3 splenectomized calves. The 
UFMG1 inoculate was rickettsia partially purified from infected IDE8 tick cells by repeated 
syringing ten times through a 26G needle to fragment cells, followed by centrifugation at 200 x g 
for 10 minutes to pellet cell debris and leave rickettsia in the supernatant. A. centrale and Gonen 
inoculates were blood cryostabilates frozen in 15 % DMSO. Once splenectomized calves reached 
over 10 % rickettsemia, infected blood was collected and used to inoculate trial cattle. This also 
standardized all strains as fully viable and blood-derived to allow for a more direct comparison 
between UFMG1 and A. centrale.  
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2.2.2. Trial design 
The trial design is outlined in Figure 1. Twelve Israeli Friesian calves (Bos taurus) were used, aged 
3-5 months at the start of the trial – close to the average age at which calves are vaccinated with A. 
centrale (Bock and de Vos, 2001). They were kept under tick- and fly-free conditions, and 
confirmed to be negative for pre-existing A. marginale and A. centrale infections by PCR and 
MSP5 competitive ELISA (cELISA) (VMRD, Pullman, WA). The Kimron Veterinary Institute 
Animals Welfare Committee and the Israeli Ministry of Health approved all experiments in cattle 
(licence number 020_b1731). 
 
Calves were randomly divided into 3 groups of 4 animals each, and subcutaneously inoculated with 
1x106 A. marginale UFMG1, 1x106 A. centrale, or 2 ml PBS alone (control). The infection was 
allowed to resolve without treatment. Sixty days after initial infection (2 weeks after the last point 
rickettsemia was ≥0.1 %), the calves were challenged with 1x107 Gonen strain rickettsia in 2 ml 
PBS. 
 
Progress of infection was monitored at least thrice-weekly, and daily during acute infection, by 
rickettsemia, hematocrit, and rectal temperature. Rickettsemia was measured in Giemsa-stained 
blood smears, using blood taken by ear vein puncture. Percentage rickettsemia was calculated by 
the number of infected erythrocytes divided by total number of erythrocytes, counted over a 
minimum of 20 fields in 100x oil immersion. Hematocrit was measured by microhematocrit 
technique (Schalm et al, 1975), using capillary blood from the ear vein. 
 
The threshold of disease severity at which cattle would be treated with antibiotics was set before the 
trial as a hematocrit remaining below 20 % for 3 days.  
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Figure 1: Design of live vaccine trial. 
 
 
2.2.3. Statistical Analysis 
The statistical significance of differences in clinical parameters between different groups was 
calculated by ANOVA and Tukey HSD post-analysis (Yandell, 1997), using the Minitab software 
package (Minitab Inc., State College, Pennsylvania, USA). 
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2.2.4. Confirmation of infection and genotype analysis 
For DNA analysis, blood samples were collected into EDTA-Vacutainers (Becton Dickinson, 
Franklin Lakes, New Jersey), diluted with an equal volume of cold PBS, and then washed three 
times in cold PBS by centrifugation at 2600 g for 20 minutes at 4 °C. The buffy coat was removed 
after each centrifugation. Packed erythrocytes were resuspended in an equal volume of PBS and 
frozen at -70 °C to lyze the cells. Samples were then thawed to room temperature, and DNA 
extracted by the QiaAmp DNA Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's 
instructions. The DNA concentration post-extraction was measured by NanoDrop 
spectrophotometer (NanoDrop ND-1000, PeqLab Erlangen, Germany).  
 
All PCR primers and reaction conditions are described in detail in Table 1. Initial confirmation of A. 
marginale infection was through a real-time msp1b PCR, as described by Carelli et al. (2007). A. 
centrale does not have an MSP1 protein, so a conventional msp4 PCR was used to confirm A. 
centrale infection, after Shkap et al. (2008).  
 
A. marginale strains are typically characterized by the amino acid sequence of their MSP1a tandem 
repeat region (reviewed by Cabezas-Cruz et al., 2013). The msp1a sequence of A. marginale in 
infected animals was amplified by a hemi-nested PCR as described by Lew et al. (2002). For 
animals with a dual infection of A. marginale Gonen and UFMG1 strains, the shorter UFMG1 
msp1a tandem repeat sequence was preferentially amplified. Therefore in dual infections with 
Gonen and UFMG1 strains, Gonen msp1a was amplified using the original reverse primers, and 
self-designed forward primer F2, which was specific for the Gonen strain msp1a (based on 
sequences successfully amplified from singly-infected cattle).  
 
All conventional PCRs used the same reaction mixture, namely a final volume of 50 μl containing: 
5 μl purified DNA as template, 1× PCR buffer, 1 μM of each primer, 0.2 mM of each 
deoxynucleotide triphosphate, and 1.25 U of HotStar Taq (all from Qiagen, Hilden, Germany). The 
reaction was performed in a Eppendorf Mastercycler (Eppendorf, Hamburg, Germany), and PCR 
products were visualized on a 2 % agarose gel dyed with 1x Gel Red™ Nucleic Acid stain (Biotium 
Hayward, USA). The real time msp1b PCR used a final volume of 25 μl, containing: 5 μl purified 
DNA as template, 1 x TaqMan Gene Expresssion Mastermix (Applied Biosystems, USA), 0.9 μM 
of the forward and reverse primers, and 0.2 μM of the probe. Reactions were performed in a 7500-
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fast-Real-Time PCR System (Applied Biosystems, Darmstadt, Germany). 
 
Table 1: PCR conditions for all assays used to test trial samples. 
 
Positive msp1a samples were purified using QIAquick PCR Purification Kit (Qiagen, Hilden, 
Germany) according to the manufacturer's protocol, and sequenced (in forward and reverse 
directions) by Eurofins MWG Operon (Ebersberg, Germany), using 1733F and 2957R primers for 
UFMG1, and F2 and 2957R primers for Gonen. Results were analyzed by Chromas Lite®, reverse 
sequences were reversed and complemented with Reverse Complement 
(http://www.bioinformatics.org/sms/rev_comp.html), and alignment performed with ClustalW2 
PCR target 
(purpose) 
Primers Reaction conditions Reference 
A. marginale 
msp1b 
(Pre-trial screen 
and initial 
confirmation of 
infection) 
AM-For TTGGCAAGGCAGCAGCTT,  
AM-Rev TTCCGCGAGCATGTGCAT,  
probe AM-Pb6FAM-
TCGGTCTAACATCTCCAGGCTTTCAT-
BHQ. 
95 °C for 10 min; 45 cycles of  95 °C 
for 45 s, and 60 °C for 1 min. 
Carelli et al. 
(2007) 
A. centrale msp4 
(confirmation of A. 
centrale infection) 
F: CATGGGGCATGAATCTGTG,  
R: AATTGGTTGCAGTGAGCGC 
95 °C for 3 min; 35 cycles of 98 °C for 
10 s, 55 °C for 30 s, and 72 °C for 
30 s; with final extension at 72 °C for 
5 min. 
Shkap et al. 
(2008) 
A. marginale 
msp1a (strain 
identity, sequence 
changes) 
Hemi-nested PCR: initial reaction used 
1733F—
5′TGTGCTTATGGCAGACATTTCC3’ and 
3134R—
5′TCACGGTCAAAACCTTTGCTTACC3′. 
Second reaction used 1733F and  
2957R—
5′AAACCTTGTAGCCCCAACTTATCC3′ 
95 °C for 15 minutes; 40 cycles of 
94 °C for 30 s, 55 °C for 60 s, and 
72 °C for 120 s; with final extension at 
72 °C for 7 min. The second reaction 
(using 5μl of the first reaction as a 
template) was as above but used an 
annealing temperature of 60 °C instead 
of 55 °C.  
Lew et al. 
(2002) 
A. marginale 
msp1a, specific for 
the Gonen strain. 
Hemi-nested PCR: Initial reaction used F2 - 
5’CGTATGTTACAATCAGGCACGCTG3’ 
and 3143R (see above). Second reaction used 
F2 and 2957R (see above).  
Reaction conditions as with general A. 
marginale msp1a PCR above. 
None 
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(http://www.ebi.ac.uk/Tools/msa/clustalw2/). The amino acid sequence of the tandem repeat region 
was determined by ExPASy translate (http://web.expasy.org/translate/). 
 
2.3. RESULTS 
 
2.3.1. Clinical response to initial infection with A. marginale UFMG1 and A. centrale 
The rickettsemia, hematocrit, and temperature of calves in response to UFMG1 or A. centrale 
infection are summarized in Table 2. On average, calves infected with UFMG1 developed a clearly 
detectable rickettsemia (≥0.1 %) 24 days post infection, while A. centrale rickettsemia was 
detectable after 35 days. Once infection was detected, the rickettsemia remained measurable for 
around an average 32 days for UFMG1 and 13 days for A. centrale, peaking at an average of 10% 
for the UFMG1 group, and 5 % for the A. centrale group.  
 
UFMG1 infection caused a more pronounced drop in hematocrit than A. centrale.  UFMG1-infected 
calves had minimum hematocrits of 18-21 %, compared to minimums of 21-33 % for A. centrale-
infected calves, and 28-31 % for control group calves. This represents an average reduction of 13 % 
hematocrit points (39% of total) for UFMG1-infected calves, 7.5% points (20.3% of total), for A. 
centrale-infected calves, and 5 % (13.2 % of total) for the control group. The rate of decrease in 
hematocrit was twice as fast for UFMG1 as for A. centrale.  
 
In all groups the animals had similar maximum body temperatures, with no significant differences 
between them. 
 
For both peak rickettsemia and minimum hematocrit, UFMG1 group values were significantly 
different from the control group (p<0.01), whereas A. centrale group values were not (p>0.05). All 
infections spontaneously resolved without antibiotic treatment (pre-determined treatment threshold 
described in Methods).  
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2.3.2. Clinical response after challenge 
The Gonen strain caused relatively mild infection in all groups, and no calf showed disease 
symptoms severe enough to require treatment. Post-challenge rickettsemia, hematocrit, and 
temperature are summarised in Table 2. The average clinical response to initial infection and 
challenge for each group are shown in Figure 2. 
 
Table 2: Summary of average clinical parameters for all groups, during initial infection with 
UFMG1 or A. centrale, and during challenge with the Gonen strain. 
 
Rickettsemia after challenge was low in all groups – no individual calf exceeded 7 %, and the group 
averages were 2.6 % for UFMG1, 1.0 % for A. centrale, and 3.0 % for the control group. There was 
high variability within each group, as shown in Figure 2, and no statistically significant difference 
was seen between any of the groups. 
 
The UFMG1 and control groups showed a similar level of red blood cell loss after challenge. Their 
minimum hematocrit values ranged between 19-24 % (average reduction of 12 % points) and 20-26 
% (average reduction of 13 % points) respectively. Calves in the A. centrale group were less 
affected, with minimum hematocrit values between 22-32 % (average reduction of 5 % points), and 
only one calf showing a similar level of red blood cell loss to the UFMG1 and control groups (see 
Figure 3). There was a significant difference between minimum hematocrit values of UFMG1 and 
A. centrale infected calves after challenge (p<0.05), but neither UFMG1 nor A. centrale groups 
were significantly different from the control group. There were no significant differences in body 
temperature between the groups post-challenge. 
Period Group 
Peak  
rickettsemia 
(%) 
Days to 
peak  
rickettsemia 
Days of  
measurable  
rickettsemia 
(≥0.09%) 
Minimum 
hematocrit 
(%) 
Percentage 
hematocrit 
reduction (% 
of total) 
Maximum 
temperature 
(°C) 
Initial UFMG1 10 ± 3.1 29±3 32 ± 4 19.8 ± 1.5 39.4 ± 12.2 39.8±0.25 
infection A. centrale 5 ± 3.6 39±4 13 ± 1 26 ± 5.3 20.3± 25.6 39.6±0.51 
 Control 0 ± 0 n/a 0 ± 0 29± 1.2 13.2 ± 14.0 39.5±0.52 
Gonen UFMG1 2.6 ± 3.2 28±2 15 ± 11 21.5 ± 2.4 34.3± 12.7 40.4± 0.77 
challenge A. centrale 1.0 ± 1.4 33±2 4 ± 4 28.3 ± 4.3 15.3 ± 13.1 40.1±0.95 
 Control 3.05 ± 3.1 29±6 20 ± 17 22 ± 2.8 37.2 ± 3.5 39.8±0.36 
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Figure 2: The course of rickettsemia, hematocrit, and temperature over initial infection and 
challenge (median values/group) for (A) UFMG1 group, (B) A. centrale group, and (C) control 
group. Arrow indicates point of challenge. 
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Multiple calves, even in the control group, showed low levels of rickettsemia after challenge. 
Nonetheless, Gonen still caused similar levels of hematocrit reduction as the initial infection with 
UFMG1 despite having lower rickettsemia (Figure 2).  
 
Figure 3: Peak rickettsemia (A) and minimum hematocrit (B) post-challenge. Horizontal bars 
represent median group value. * = p<0.05 significance of difference between groups. 
 
Within all groups, the individual response to initial infection and challenge was highly variable, as 
can be seen in Figure 3. This was particularly noticeable for the levels of rickettsemia. There was no 
significant correlation between the severity of symptoms during initial infection, and their severity 
after challenge (data not shown).  
 
2.3.3. Establishment and persistence of infection 
All calves inoculated with A. marginale UFMG1 or A. centrale remained infected throughout the 
whole trial (four months in total for initial infection and challenge). After challenge, all calves but 
one became PCR-positive for the Gonen strain, and the infection remained detectable until the trial 
ended, two months after challenge. One animal in the UFMG1 group (calf #1) did not become PCR-
positive for the Gonen strain at any point after challenge – this calf also showed no disease 
symptoms after challenge. 
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MSP1a genotype over the course of initial infection and challenge 
UFMG1 and Gonen MSP1a tandem repeat sequences remained stable in almost all calves over the 
course of infection, whether the host was infected with one strain or two. There was one exception: 
post-challenge, one animal in the A. centrale group showed a single nucleotide base change in the 
Gonen strain msp1a, giving rise to a single amino acid change in the MSP1a amino acid tandem 
repeat sequence. The MSP1a tandem repeat sequences of A. marginale UFMG1 and Gonen strains 
are illustrated in Table 3; A. centrale does not have an msp1a gene.  
 
Table 3: MSP1a tandem repeat structure in UFMG1 and Gonen strains.  
(A): Original and altered A. marginale UFMG1 and Gonen MSP1a tandem repeats.  
(B):  amino acid sequences of tandem repeats. Nomenclature according to that proposed by de la 
Fuente et al. (2007) and tandem repeat numbers updated by Cabezas-Cruz et al. (2013) – tandem 
repeat sequence 162 has not previously been described. 
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2.4. DISCUSSION 
2.4.1. Response to initial infection with UFMG1 vs. A. centrale 
UFMG1 infection gave rise to symptoms which were not severe enough to require intervention. But 
the symptoms were greater than those from A. centrale, and came close to the predetermined 
threshold for antibiotic treatment. This level of disease was similar to that seen in the calf from 
which UFMG1 was originally isolated (Ribeiro et al., 1997), and less severe than that seen in the 
calves infected in the initial UFMG1 protection trial by Bastos et al. (2010).  
 
Unfortunately, inactivation of UFMG1 appears to abrogate any protective effect it causes. A study 
by Lasmar et al. (2012) using cell culture-derived UFMG1 as a beta-propiolactone-inactivated 
vaccine demonstrated no protection against the pathogenic Brazilian strain UFMG2. In contrast, 
live cell culture-derived UFMG1 induced significant protection against UFMG2 under otherwise 
similar conditions (Bastos et al., 2010).  
 
While UFMG1 appears unlikely to cause fatal disease in calves at the target age for vaccination, 
any pronounced pathogenicity raises concerns about its safety as a live vaccine. The calves used in 
this trial were under one year old; this is the stage at which live vaccination is recommended as any 
symptoms tend to be mild (Bock and de Vos, 2001). If, however, a vaccine strain is transmitted 
from vaccinated calves to naïve adult cattle by tick or mechanical transmission, the disease is very 
likely to be fatal in the adult – as seen in experimental infection of adult cattle with A. centrale 
(Pipano et al., 1985).  
 
The risk of accidental infection of naïve adults occurring after A. centrale vaccination is limited by 
its extremely restricted biological transmission - only reported to date with the African tick 
Rhipicephalus simus, from which it was initially isolated (Theiler, 1912; Potgieter and Van 
Rensburg, 1987), and at an extremely low transmission efficiency by Dermacentor andersoni (Ueti 
et al.,2009). Several other tick species that act as A. marginale vectors cannot transmit A. centrale, 
namely Hyalomma excavatum, R. sanguineus, and R. (Boophilus) annulatus (Shkap et al., 2009).   
 
Gonçalves-Ruiz et al. (2005) showed that A. marginale UFMG1 was not transmitted by 
Rhipicephalus (Boophilus) microplus ticks, which are the major biological vector of A. marginale in 
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Brazil. However, A. marginale is known to be transmissible by at least 20 tick species (Kocan et al., 
2010), and mechanical transmission is always a possibility; therefore any further studies on 
UFMG1 as a live vaccine should investigate both its transmissibility by other tick vector species, 
and the effect of UFMG1 infection on adult cattle.  
 
2.4.2. Protection from challenge 
Previous UFMG1 infection had a negligible effect on disease caused by the Gonen strain. The lack 
of protection from UFMG1 against the heterologous Israeli Gonen strain tested here contrasts with 
the complete protection that UFMG1 induced against the high pathogenic Brazilian strain  UFMG2 
(Bastos et al., 2010). UFMG1 infection caused significantly less reduction in disease symptoms 
after challenge than A. centrale, the current live vaccine of choice, and so does not appear to be a 
candidate for replacing it.  
 
The low pathogenicity of the Gonen strain in this trial made assessing protection from fatal 
infection impossible. The Gonen strain was selected due to its high prevalence in Israel (Molad et 
al., 2009), and the serious symptoms seen after deliberate infection of splenectomized cattle with 
this strain (V. Shkap, unpublished results described in Methods).  However, splenectomized cattle 
are much more susceptible to anaplasmosis (Kocan et al., 2003), and from the symptoms seen here 
the Gonen strain cannot be considered highly pathogenic in intact calves. The young age of the 
calves used here is also likely to explain the lower symptoms – although some A. marginale strains 
such as UFMG2 can induce serious disease in young calves (Bastos et al., 2010), in general 
symptoms of anaplasmosis will be milder in younger animals. If time and money had permitted, 
Gonen infection should have been tested before the trial with an intact calf of the same age as those 
used in the trial, to confirm the pathogenicity of the strain in conditions more similar to the trial. 
The optimum scenario would have been to vaccinate the calves and then wait until they were at 
least one year old before challenging them with the Gonen strain. However, keeping the calves in 
tick and fly-free conditions for this length of time would be prohibitively expensive. 
 
Nonetheless, although the Gonen strain could not be used to assess protection from fatal levels of 
disease, in this trial it caused a similar level of symptoms as the challenge strains used in several 
other vaccine studies (Kocan et al., 2001; de la Fuente et al., 2002). The inclusion of A. centrale 
provided a benchmark to compare how UFMG1 reduced the symptoms of Gonen infection. Given 
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that UFMG1 was less effective than A. centrale, and A. centrale is itself reported to have problems 
protecting cattle against some highly virulent A. marginale strains (Carter et al., 2006), it seems 
unlikely that UFMG1 would have induced significant protection against a more pathogenic strain.  
 
2.4.3. Variation in response to infection 
There was considerable variation within each group for the level of disease caused by initial 
infection with UFMG1 or A. centrale, and then for the level of protection against the Gonen strain. 
For example, while the majority of the A. centrale group had mild or no disease after challenge, one 
calf appeared unprotected, with a similar level of symptoms as the unvaccinated calves of the 
control group. Such a varied response to the A. centrale vaccine has frequently been reported in the 
field (Bock and de Vos, 2001). One controlled study showed considerable variation even when 
identical inocula were used: when Wilson et al. (1980) infected 18 cattle with A. centrale, 10 were 
protected, the other 8 were not. This high variability in response should not be unexpected in cattle, 
as the animals are not specifically inbred for laboratory studies. But it does highlight the difficulties 
in finding a vaccine capable of inducing complete coverage across a diverse population, where there 
may be genetic predisposition to vulnerability or resistance. 
 
Some other naturally low pathogenic A. marginale strains have been previously proposed as live 
vaccines: the Dawn strain from Australia (Bock et al. 2003; Carter et al., 2006), and the Yucatan 
strain from Mexico (Rodriguez et al. 2008). However, despite promising early results neither has 
yet progressed into wider use. In the case of the Dawn strain, it showed greater protection than A. 
centrale against a heterologous Australian strain (Bock et al., 2003), but was not protective against 
a high pathogenic African strain (Carter et al., 2006). The Mexican Yucatan strain has not been 
tested against strains from outside Mexico. It increasingly appears that the prospect of a globally 
effective anaplasmosis vaccine still remains distant.  
 
There are many potential live A. marginale vaccines, including UFMG1, that are effective against 
heterologous strains from the same geographic area, and are likely to have a longer lasting effect 
than killed vaccines. These could be useful vaccines when targeted to their area of efficacy. But 
such 'local' vaccines are a poor business investment, and with cattle movement spreading A. 
marginale strains around the world, they are far from guaranteed to stay fully effective. 
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2.4.4. MSP1a tracking 
UFMG1 and Gonen strains established a co-infection in three out of four calves in the UFMG1 
group. Infection exclusion doesn't appear to happen between these two strains, suggesting that they 
do not have overlapping msp2 pseudogene repertoires (Futse et al., 2008). This ensures that the 
protection (or lack thereof) measured here is likely to be due to aspects of the immune response 
other than MSP2 reactivity.  
 
The single calf in the UFMG1 group which did not establish a Gonen infection after challenge is an 
interesting case. It is unlikely to be due to infection exclusion, as this was not seen in any of the 
other calves in the group. It is possible that it had an unusually effective immune response to 
UFMG1 infection (see Chapter 3). This calf should have been re-challenged after the main trial was 
over, to determine if it was a chance occurrence or a true example of sterile immunity. 
 
The MSP1a tandem repeat sequence is used as a way to track strain identity because it shows 
sufficient global variation to be a good marker of different strains, but remains constant within both 
the cattle and tick hosts, and over transmission between them (as reviewed by Cabezas-Cruz et al., 
2013). The minor Gonen msp1a genotype change seen here in one calf co-infected with A. centrale 
may be only a single nucleotide change, but since the sequencing was done from total PCR product 
rather than cloned sequences, it was apparently the new predominant sequence in that calf.  
 
The small tandem repeat change upon co-infection is similar to that seen by Bastos et al. (2010) in 
cattle co-infected with UFMG1 and UFMG2. A variant UFMG2 msp1a genotype had two tandem 
repeats with a one nucleotide change leading to one amino acid change. De la Fuente et al. (2001) 
proposed slip-strand mispairing as a mechanism for generating new msp1a tandem repeats, with 
duplications and deletions of entire or partial tandem repeat sequences. Although small, the single 
base changes seen in this study and in Bastos et al. (2010) could also represent an example of the 
generation of new sequences through small nucleotide changes, which accumulate to contribute to 
the many tandem repeat sequences characterized to date (Cabezas-Cruz et al. 2013). It is interesting 
to speculate whether co-infection is a particular driver in this variation, as no changes were seen in 
singly-infected animals. But with only one co-infected calf showing a variant sequence, no firm 
conclusion can be drawn on this. 
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2.4.5. Conclusions 
UFMG1 infection produced greater side effects than A. centrale, casting doubt on its safety as a live 
vaccine. Moreover, it had a limited effect on symptoms of disease caused by the geographically 
distant Israeli Gonen strain, suggesting it may not effectively protect cattle against distantly related 
A. marginale strains. The relatively low pathogenicity of the Israeli Gonen strain in this trial makes 
it impossible to determine if UFMG1 could have reduced fatal disease, but overall it does not 
appear to be a strong candidate to replace A. centrale as a live vaccine against anaplasmosis in 
Israel. 
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CHAPTER 3: SEROLOGICAL RESPONSE TO INFECTION WITH 
A. MARGINALE OR A. CENTRALE 
 
3.1. INTRODUCTION 
 
3.1.1. The importance of the antibody response in protection against bovine anaplasmosis 
The antibody response plays an important role in protecting cattle from anaplasmosis. Although it 
must work in conjunction with other parts of the immune system to be protective (Gale et al., 1992), 
a high antibody response – and in particular a strong IgG2 response - has previously been identified 
as a correlate of protection against bovine anaplasmosis after vaccination (reviewed by Palmer et 
al., 1999).  
 
3.1.2. Characteristics of a protective antibody response  
A correlation between the strength of the IgG response to vaccination and subsequent protection 
from disease has been seen in several studies (Wilson et al., 1980; Tebele et al., 1991; Brown et al., 
1998). However, the challenge strains used in these studies were either homologous (Tebele et al., 
1991; Brown et al., 1998) or antigenically very similar (Wilson et al., 1980) to the vaccine strains. 
Many candidate A. marginale vaccines are first tested against homologous challenge strains, 
because heterologous challenge is frequently unsuccessful (Kuttler et al., 1984; Palmer et al., 1994; 
Carter et al., 2006; Ocampo-Espinoza et al., 2006). Therefore the cross-reactivity of the antibody 
response to infection with live vaccine strains has hardly been investigated. In this trial, the relative 
cross-reactivity of the antibody response to UFMG1 and A. centrale is likely to be a critical factor 
in their effectiveness against the heterologous Israeli Gonen challenge strain. 
 
Cattle have two IgG subclasses: IgG1 and IgG2. Several previous studies have shown that an IgG2-
biased antibody response is associated with protection from anaplasmosis (Brown et al., 1998; 
Barigye et al., 2004; Vega et al., 2007). Palmer et al. (1999) proposed that the importance of IgG2 
was its effectiveness in opsonising bacteria, leading to more rapid clearance of A. marginale. 
Opsonophagocytosis (antibody-enhanced phagocytosis) has been demonstrated in vitro with A. 
marginale and immune sera (Cantor et al., 1993; Melendez 2005). In cattle, both IgG1 and IgG2 
can increase phagocytosis; however, IgG2 is considerably more rapid and effective at enhancing 
phagocytosis by neutrophils and peripheral blood monocytes (McGuire and Musoke, 1981).  
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The main model of protective immunity largely drew on the results of immunization with killed or 
outer membrane protein (OMP) vaccines (Palmer et al., 1999). Despite the success of A. centrale 
(Bock et al., 2003), relatively little research on correlates of protection against anaplasmosis has 
been derived from live vaccines. Research on the immune response to A. centrale has largely 
focused identifying conserved antigens between A. centrale and A. marginale (Agnes et al., 2011), 
to inform the development of future recombinant protein vaccines. But more basic immunology 
research on why A. centrale is less pathogenic and more protective than A. marginale could clarify 
which properties are most important for an effective vaccine to induce.  
 
3.1.3. Aims 
From the clinical results of the live vaccine trial (Chapter 2), A. centrale infection caused less 
serious symptoms than UFMG1 infection, and had more of a protective effect against disease after 
challenge with the Israeli Gonen strain. The antibody response to infection with UFMG1 and A. 
centrale will be investigated to examine the underlying causes of these differences. In particular, the 
strength, subclass, and cross-reactivity of the antibody response will be investigated to determine 
how these factors correlate with protection or pathology. This will provide information on the 
underlying factors behind the clinical results described in Chapter 2, and increase knowledge of the 
antibody response to live vaccines against anaplasmosis. 
 
 
3.2. MATERIALS AND METHODS 
 
3.2.1. Sample collection 
For serological tests, blood samples were collected weekly in Serum Separation Vacutainer tubes 
(Becton Dickinson, Franklin Lakes, New Jersey, USA), and processed according to manufacturer’s 
instructions. Sera samples were stored at -70 ºC until tested. 
 
3.2.2. Source of A. marginale and A. centrale antigen material 
The Anaplasma antigenic material used for ELISA assays was derived from infected blood or tick 
cell culture. Infected blood came from the splenectomised calves used as sources of inocula in the 
trial (as described in Chapter 2). Tick cell cultures of A. marginale UFMG1 and UFMG2 have been 
continuously maintained in IDE8 tick cells for approximately 5 years at the Universidade Federal de 
Minas Gerais, Brazil, and Ludwig-Maximilians-Universität München, using standard culture 
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methods described by Bastos et al. (2010). Tick cell cultures of A. marginale Gonen were initiated 
from a blood sample taken from the splenectomised calf used to provide inoculum for the trial 
(K.Lis, manuscript in preparation). 
 
3.2.3. Measurement of seroconversion 
Seroconversion of infected calves was measured using an anti-MSP5 competitive ELISA (VMRD, 
Pullman, WA). Samples were tested according to manufacturer’s instructions.  
 
3.2.4. IgG ELISAs 
Antigen preparation 
IgG levels against A. marginale or A. centrale were measured by an indirect ELISA using purified 
rickettsia as the coating antigen, adapted from the protocol described by Shkap et al. (1990). The 
rickettsia were purified from infected blood or IDE-8 tick cell cultures (sources described in 3.2.2.). 
Purification from blood used a protocol similar to that of Palmer and McGuire (1984). Briefly, 
blood was collected in EDTA Vacutainers (Becton Dickinson, Franklin Lakes, New Jersey, USA), 
diluted into an equal volume of cold PBS, and then washed three times in cold PBS by 
centrifugation at 2600 g for 20 minutes at 4 °C. The buffy coat was removed after each 
centrifugation. Packed erythrocytes were resuspended in an equal volume of PBS and frozen at -70 
°C to lyse the cells. The samples were then thawed at room temperature, and washed in PBS eight 
times by centrifugation at 23000 g for 15 minutes at 4 °C (Sorvall SS-34 rotor, Thermo), until no 
visible pink haemoglobin remained in the pellet. The final pellet was resuspended in 20 ml PBS, 
sonicated at 100 W for 2 minutes, and spun at 500 g for 5 minutes at 4 °C. The supernatant was 
retained, and pelleted at 5000 g for 10 minutes at 4 °C. This pellet containing purified rickettsia was 
resuspended in 1ml PBS, and protein concentration measured by Bradford protein assay (Sigma, 
Munich, Germany).  
 
A. marginale was purified from infected IDE-8 tick cell cultures using a Percoll (GE Healthcare, 
Uppsala, Sweden) density gradient (K.Lis, manuscript submitted). Briefly, cell cultures at >70 % 
infection were centrifuged at 3000 g for 20 minutes to pellet infected cells and rickettsia. The pellet 
was resuspended in Tris-Sucrose buffer (33 mM Tris-HCl, 0.25 M sucrose, pH 7.4), and 
homogenized for 2 minutes in a Dounce homogenizer to disrupt cells and release the rickettsia. The 
homogenate was then spun at 200 g for 10 minutes to pellet the larger cell debris, and the 
supernatant containing rickettsia and smaller cell debris retained. The supernatant was layered over 
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30 % Percoll diluted in 0.25 M sucrose, and centrifuged at 25000 g for 60 minutes. The upper layer 
containing cell debris was removed, and the cloudy base layer containing rickettsia retained. The 
rickettsia were washed twice with PBS (15000 g, 15 minutes), resuspended in a small volume of 
PBS, and protein concentration measured by Bradford protein assay. 
 
Total IgG ELISA 
High protein binding microtiter plates (Nunc, Rochester, New York, USA) were coated with 100 μl 
of 5 μg/ml A. marginale or A. centrale antigen diluted in carbonate/bicarbonate buffer pH 9.5, and 
incubated overnight at 4 °C. After washing 4 times with PBS with 0.05 % Tween 20 (PBS-T), plates 
were blocked with 200 μl diluent (5 % heat-inactivated horse serum in PBS-T) for 2 hours at room 
temperature (RT), shaking. 100 μl of each serum sample was then added at a final 1:80 dilution. 
After incubation and wash steps as before, 100 μl rabbit anti-bovine IgG conjugated to alkaline 
phosphatase (Thermo Scientific, Waltham, Massachusetts, USA) was added at 1:5000 dilution, and 
incubated as before. After washing, 100 μl p-nitrophenyl phosphate (pNPP) substrate in 
diethanolamine buffer (Thermo Scientific, Waltham, Massachusetts, USA) was incubated for 30 
minutes, and the reaction stopped by the addition of 50 μl 2N NaOH. Absorbance values were read 
at 405 nm using a LEDETECT 96 plate reader (Labexim Products, Lengau, Austria). 
 
Subclass IgG ELISA 
The protocol for the IgG subclass ELISA was identical to the total IgG ELISA for antigen coating, 
blocking, and sera addition steps. A dilution series of an IgG reference sample (Bethyl Laboratories, 
Montgomery, Texas, USA) with known concentrations of IgG1 and IgG2 was also added, to allow 
the concentration of IgG1 and IgG2 in the test samples to be calculated from the standard curve. 
Then 100 μl of sheep anti-bovine IgG1 or anti-bovine IgG2 (Bethyl Laboratories, Montgomery, 
Texas, USA) diluted to 1:15000 was incubated for 90 minutes at RT before plates were washed 4 
times. 100 μl donkey anti-sheep IgG conjugated to horseradish peroxidase was added at 1:100000 
and plates incubated and washed as in the previous step. 100 μl of 3,3′,5,5′-tetramethylbenzidine 
(TMB) substrate (Sigma, Munich, Germany) was added and the reaction allowed to develop for 30 
minutes, before being stopped by addition of 100 μl 1N HCl. Absorbance values were read at 450 
nm (reference wavelength 690 nm) by a LEDETECT 96 plate reader. 
 
3.2.5. Data analysis 
Antibody levels were expressed as either raw absorbance values; fold change, calculated by: 
absorbance of immune sample divided by absorbance of pre-immune sample; or antibody 
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concentration (μg/ml), calculated from the standard curve of the IgG reference. The Minitab 
software package (Minitab Inc., State College, Pennsylvania, USA) was used for statistical analysis. 
ANOVA and Tukey HSD post-analysis were used to calculate the significance of parameter 
differences between groups (Yandell, 1997). Linear correlations between parameters were 
calculated by the Pearson product-moment correlation coefficient. 
 
 
3.3. RESULTS 
 
3.3.1. Seroconversion 
Serum samples from the trial were tested with an anti-MSP5 competition ELISA as a confirmation 
of infection and an initial assessment of immune response. All calves were seronegative before the 
trial started. After infection with UFMG1 or A. centrale, they rapidly seroconverted, and antibody 
levels remained high until point of challenge and beyond. When undiluted serum samples were 
tested (as by manufacturer’s instructions), infection with UFMG1, A. centrale, and Gonen induced 
similar antibody levels, all reaching a maximum inhibition level of around 90 %. To determine 
whether these samples had reached the maximum inhibition level of the cELISA, samples were 
diluted 1:64. Under these conditions (shown in Figure 1), UFMG1 and Gonen both induced higher 
anti-MSP5 total antibody levels than A. centrale, although after challenge the anti-MSP5 antibody 
levels of A. centrale-infected calves rose to reach a similar level to UFMG1-infected calves. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Seroconversion after infection, measured by MSP5 cELISA with samples diluted 1:64. 
Each data point represents the average value for each group of four calves. Arrow indicates point of 
challenge with Gonen strain. 
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3.3.2. Total IgG ELISA development 
The ELISA for total levels of IgG against A. marginale or A. centrale was optimized for several 
factors: antigen concentration, coating buffer, blocking buffer (horse serum, foetal bovine serum, 
bovine serum albumin) and serum concentration. An antigen concentration equivalent to 5 μg/ml 
extracted protein was found to be the best condition for high absorbance values without using 
excessive quantities of antigen (data not shown). A carbonate/bicarbonate coating buffer (pH 9.5) 
was slightly more effective than PBS (data not shown). A blocking buffer of 5 % inactivated horse 
serum was the most effective (data not shown), and produced a sigmoidal serum dilution curve, as 
shown in Figure 2. To conserve limited serum volumes, a single dilution of 1:80 was selected from 
the linear portion of the dilution curve, and used for all samples in future assays.  
 
 
Figure 2: Dilution curve of representative serum samples, using 5 % heat-inactivated horse serum 
as diluent. Final concentration used for future assays shown by dashed line. 
 
Antigen purified from red blood cells or tick cell cultures gave statistically similar results, as seen in 
Figure 3. However, A. centrale cannot be cultivated in vitro and must be derived from red blood 
cells. Therefore to allow a better comparison between strains, red blood cell-derived rickettsia were 
used for all assays unless otherwise stated.
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Figure 3: Comparison of tick-cell 
derived and blood-derived rickettsia 
(Gonen strain) as IgG ELISA antigen. 
Correlation was statistically significant 
(Pearson correlation co-efficient 
r=0.93, r2=0.87, p<0.01). 
 
 
 
 
 
 
 
3.3.3. IgG response to the homologous strain 
Figure 4 shows the maximum IgG response of each calf after infection with UFMG1, A. centrale or 
Gonen (for the latter, samples were taken from control group post-challenge), when tested against 
homologous strain antigen. UFMG1 infection had the lowest IgG response (average 3-fold increase 
above pre-immune levels). The response to Gonen infection was higher (5.1-fold increase), and the 
A. centrale response the highest (7-fold). There was considerably more variation in the latter two 
groups, each having both high- and low-responding calves.  
 
 
Figure 4: Maximum IgG response against 
homologous strain antigen after infection 
with UFMG1, A. centrale, or Gonen. 
Response to UFMG1 and A. centrale 
infection were significantly different (* = 
p<0.05 for group difference). Bar represents 
median value for the group. 
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3.3.4. IgG response to the challenge strain 
Serum samples from all groups were tested for IgG reactivity to the Gonen challenge strain. 
Maximum anti-Gonen IgG levels during infection with UFMG1, A. centrale or Gonen are shown in 
Figure 5. The antibody response to UFMG1 infection had minimal cross reactivity with the Gonen 
strain, while the antibody response to A. centrale had a significantly higher level of binding to 
Gonen antigen (p<0.05). The cross-reactivity of the IgG response correlated significantly with 
protection from disease symptoms. The higher the level of cross-reactive IgG against the Gonen 
strain induced during initial infection with UFMG1 or A. centrale, the lower the subsequent drop in 
hematocrit after challenge with the Gonen strain (p<0.05; see Figure 6). 
 
 
Figure 5: Maximum IgG response 
against Gonen strain antigen. 
Cross-reactive response to UFMG1 
and A. centrale infection were 
significantly different (* = p<0.05 
for group difference). Bar represents 
median value for the group. 
 
 
 
 
 
 
Figure 6: Correlation between the 
cross-reactivity of the IgG response to 
UFMG1 or A. centrale (measured by 
maximum fold change in anti-Gonen 
IgG during initial infection) and 
subsequent drop in hematocrit values 
after challenge with Gonen. Pearson 
correlation co-efficient r=-0.744, 
r2=0.554, p<0.02.
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3.3.5. Cross-reactivity of the UFMG1 IgG response against Brazilian vs. Israeli strains 
 In a previous study of UFMG1 as a live vaccine (Bastos et al, 2010), UFMG1 infection had a 
protective effect against challenge with the high pathogenic Brazilian strain UFMG2. Therefore the 
antibody response to UFMG1 in this trial was tested for reactivity against both UFMG2 and Gonen 
strain antigen. The homologous response to UFMG1 antigen was used as a positive control.  
 
The IgG response after UFMG1 infection had similar reactivity to UFMG1 and UFMG2 antigen. 
The IgG reactivity to UFMG2 was slightly, but non-significantly, lower than reactivity to the 
homologous strain UFMG1. In contrast, as seen in Figure 7, IgG cross-reactivity to the Israeli 
Gonen strain was significantly lower than IgG reactivity to both the Brazilian strains UFMG1 and 
UFMG2. 
 
Figure 7: The IgG response to UFMG1, UFMG2, 
and Gonen antigen (all derived from IDE8 cell 
culture). Horizontal bar represents median value. 
Significance of difference between conditions: *= 
p<0.05; **=p<0.01. 
 
 
 
 
 
 
3.3.6. IgG subclass of the antibody response 
The time points with the highest total IgG levels after infection with UFMG1, A. centrale, or Gonen 
alone were tested for relative levels of IgG1 and IgG2. As shown in Figure 8, levels of IgG1 and 
IgG2 were similar for the majority of samples. The A. centrale response had more calves with 
greater IgG2 than IgG1, while the response to the UFMG1 and Gonen strains had more IgG1. 
However, the differences in IgG1:IgG2 between groups were non-significant. A greater IgG2 
concentration and greater IgG2 bias in the response to initial infection were significantly correlated 
with a reduced loss of red blood cells after challenge (p<0.05; see Figure 9), but there was no 
significant association with temperature or rickettsemia. There was no significant correlation 
between IgG1:IgG2 or IgG2 concentration in post-challenge serum samples and the clinical 
response post-challenge (data not shown).
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Figure 8: IgG1 and IgG2 antibody responses to infection with UFMG1 (calves 1-4, samples taken 
from the UFMG1 group before challenge with Gonen), A. centrale (calves 5-8, samples taken from 
the A. centrale group before challenge with Gonen), or Gonen alone (calves 9-12, samples taken 
from the control group post-challenge). 
 
 
 
Figure 9: Correlations between the level of red blood cell loss post-challenge and (A) the pre-
challenge IgG2 bias (the lower the IgG1:IgG2, the greater the IgG2 bias)(r=0.71, p<0.05) and (B) 
the pre-challenge IgG2 concentration (r=-0.62, p<0.1). 
61 
3.3.7. Dynamics of the IgG response to infection 
The dynamics of the IgG response were measured over the course of initial infection with UFMG1 
or A. centrale, and subsequent challenge with the Gonen strain. Figure 10 shows the results when 
serum samples from all groups were tested against Gonen strain antigen.  
 
 
 
 
Figure 10: Dynamics of the 
anti-Gonen IgG response to 
infection in the (A) UFMG1, 
(B) A. centrale, or (C) control 
groups. Arrow indicates the 
point of challenge with the 
Gonen strain. Similar IgG 
response dynamics were seen 
when UFMG1 and A. centrale 
group samples were tested 
against antigen from their 
respective homologous strains 
(data not shown).  
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As shown in Figure 10.A., the cross-reactive IgG response to UFMG1 peaked on average 40 days 
after infection at an average 2.7-fold increase, declined, and then peaked again at 40 days post-
challenge with a 5.7-fold increase. All calves in this group had relatively low cross-reactive anti-
Gonen IgG responses after UFMG1 infection, which then increased after challenge with the Gonen 
strain.  
 
Calves infected with A. centrale showed a more variable IgG response, as seen in Figure 10.B. The 
average fold-change in anti-Gonen IgG in response to A. centrale infection was 9.5. One calf had a 
very rapid response, peaking at 15 days post-infection; two calves peaked at around 25-30 days, and 
one (with a very low response) at around 35 days. IgG levels increased to a lower level following 
challenge with the Gonen strain, with an average 3.4-fold rise. Only one calf in this group (calf #8) 
had higher anti-Gonen IgG levels post-challenge than during initial A. centrale infection. This calf 
also had the most serious symptoms of the A. centrale group in response to challenge with Gonen. 
 
The strength of the IgG response to initial infection with UFMG1 or A. centrale appeared to 
influence how the calves responsed to challenge - both the severity of the symptoms of Gonen 
infection, and the strength of the post-challenge IgG response. Calves which had high IgG 
responses to initial infection then showed milder symptoms during Gonen infection and lower post-
challenge rises in IgG. Calves with low IgG during initial infection had more serious symptoms 
during Gonen infection and and higher rises in IgG post-challenge. Only one calf (#4 in the 
UFMG1 group) was an exception to this. It had a very high IgG response post-challenge (four-fold 
increase) and relatively mild symptoms. However, overall a higher IgG response to initial infection 
with UFMG1 or A. centrale, and then a lower IgG response to subsequent challenge with Gonen 
was significantly associated with reduced symptoms during Gonen infection (Figure 11; p<0.1). 
 
 
Figure 11: Correlation between 
relative pre/post-challenge IgG 
levels [(post-challenge max.IgG / 
pre-challenge max. IgG) *100] and 
severity of challenge response 
(minimum hematocrit after 
challenge). r = - 0.56; p<0.1. 
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3.4. DISCUSSION 
 
A. centrale gave rise to a highly cross-reactive IgG response which appeared to protect calves 
without a pronounced secondary rise in IgG levels post challenge. Despite good seroconversion 
after UFMG1 infection, the level of cross-reactive IgG induced in response to UFMG1 was low. 
This correlated with a lower level of protection from challenge with the heterologous Israeli Gonen 
strain.  
 
3.4.1. Seroconversion 
The MSP5 cELISA was used to give an early confirmation of seroconversion during the trial. 
Interestingly, results from the MSP5 cELISA contrasted with those from the total IgG ELISA. The 
MSP5 cELISA showed higher antibody levels induced by UFMG1 infection compared to A. 
centrale infection, while the IgG ELISA gave the opposite result.  
 
Measuring the IgG response against all major surface proteins, either by ELISA as used here, or by 
Western blot as in Brown et al. (1998), appears to give more valuable information on the likely 
degree of cross-protection induced by vaccination. MSP5 is a highly conserved protein, 
demonstrated by the fact that this cELISA can be used to detect antibodies after A. marginale, A. 
centrale, and A.phagocytophilum infections (Dreher et al., 2005; Molloy et al., 1999). However, A. 
marginale immunity is highly strain-specific, and antibodies against the conserved MSP5 protein do 
not appear to correlate well with protection (Agnes et al, 2011).  
 
The cELISA measures all antibody classes. Therefore the higher antibody response it showed could 
be largely due to IgM. Although IgM is mainly produced in early infection, it can persist for up to 
80 days after A. marginale infection (Klaus and Jones, 1968; Murphy et al. 1966). Therefore IgM is 
likely to increase cELISA results over the course of the whole trial. However, IgG is the main class 
of antibody that is produced after secondary exposure to an antigen. Any remaining IgM at the point 
of challenge is likely to contribute to clearance of A. marginale. But when assessing the likely long-
term effectiveness of a vaccine, IgG levels are of more interest than IgM.  
 
3.4.2. Cross-reactivity between A. marginale strains and A. centrale 
While the antibody response has been shown to be insufficient for protection on its own (Gale et al. 
1992), it still appears to be a very important component of a protective immune response. Many 
previous studies have shown a high antibody response to be associated with protection (Wilson et 
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al., 1980; Tebele et al., 1991; Brown et al., 1998). That association was also seen in this study, with 
high IgG titers correlating significantly with less severe anemia after challenge.  
 
UFMG1 infection induced only a low level of cross-reactive IgG, and had very little effect on 
disease caused by the subsequent challenge with the Gonen strain. In contrast, the A. centrale 
vaccine strain induced considerably higher levels of cross-reactive IgG and was significantly more 
protective (Chapter 2). It is hard to determine whether the higher level of anti-Gonen IgG induced 
by A. centrale infection is principally due to a fundamentally higher IgG response, or to greater 
cross-reactivity within that response. Both of these factors are likely to contribute to its success as a 
vaccine.  
 
The importance of a cross-reactive antibody response can be seen in the higher level of IgG cross-
reactivity between the Brazilian strains UFMG1 and UFMG2, and significantly lower cross-
reactivity between UFMG1 and Gonen. This corresponds to the cross-protection between the two 
Brazilian strains (Bastos et al., 2010) and the lack of cross-protection between the Brazilian 
UFMG1 and Israeli Gonen strains seen here. 
 
From the results of this study, broad antibody cross-reactivity appears to be critical for cross-
protection between heterologous strains. This suggests that in vitro measurement of antibody cross-
reactivity between different strains would be a good way of estimating cross-protection before 
clinical trials. 
 
Past tests of heterologous protection between A. marginale strains have often shown very mixed 
results, ranging from no protection (Ocampo-Espinoza et al., 2006), partial protection (Palmer et 
al., 1994; Carter et al., 2006) or reasonable reduction of disease (Tebele and Palmer 1991). The 
better results were generally seen with live vaccines. Palmer et al. (1999) proposed that live 
vaccines stimulated a broader immune response due to exposure to antigenic variants of the 
immunodominant proteins MSP2 and MSP3 which are generated during infection.  
 
It is curious that A. centrale infection induces a more cross-reactive IgG response to the Gonen 
strain than UFMG1 infection did, as A. centrale and Gonen are more distantly related than UFMG1 
and Gonen. The high, cross-reactive antibody response is likely to be a principal factor behind why 
A. centrale is a more widely protective live vaccine than low pathogenic or attenuated A. marginale 
strains (Kocan et al., 2003). However, the reasons behind the differing level of antibody response to 
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A. centrale and A. marginale remain unknown.   
 
3.4.3. Subclass of the IgG response 
In this study, a higher IgG2 response to initial infection correlated significantly with reduced 
symptoms after challenge. There were a slightly higher number of calves with an IgG2 biased 
antibody response after A. centrale infection as opposed to UFMG1 or Gonen infection. However, 
for most calves the differences between levels of the two IgG subclasses were relatively small. 
 
The association of IgG2 and protection agrees with previous studies (Brown et al., 1998; Barigye et 
al., 2004; Vega et al., 2007). These studies measured the antibody response to immunization with 
killed or OMP vaccines, rather than after live infection, as was used in this trial. When looking at 
previous studies on the subclass response after challenge with live A. marginale, the picture 
becomes less clear-cut, as there have been very few studies focusing the subclass of the IgG 
response to natural infection, and most have had very small sample sizes. Han et al. (2010) used 
two animals - both produced very similar levels of IgG1 and IgG2 in response to infection with 
South Idaho strain A. marginale. Murphy et al. (1966) studying natural infection in cattle of varying 
ages and severity of infection surprisingly found considerably higher levels of 'electrophoretically 
fast γG globulin' (IgG1) compared to 'slow γG globulin' (IgG2) during the acute phase of disease, 
and did not associate IgG subclass with severity of infection. 
 
It appears while an IgG2-biased response is still associated with protection after live vaccines, the 
IgG2 bias is much less pronounced than that seen with killed or OMP vaccines. This could be due to 
the T-cell deletion during infection (Han et al., 2010). This would reduce the number of CD4+ T-
cells producing IFNγ, which increases IgG2 production by B-cells (Estes et al, 1994; Estes and 
Brown, 2002). 
 
A possible alternative explanation is suggested by the results of Vega et al. (2007). After 
vaccination with inactivated rickettsia, the majority of calves produced high IgG2 and low IgG1. 
However, after challenge, IgG2 titers fell from high pre-challenge levels until IgG1 titers were 
higher than IgG2. They speculated that this may be due to IgG2 concentrating in the lymph nodes 
and spleen, where the elimination of A. marginale occurs. The proposal that IgG2 could be 
concentrated in immune tissues during active infection is an interesting one, and may explain the 
reason for the less pronounced IgG2 bias after live vaccines. Immunohistochemistry on spleen and 
lymph nodes for IgG subclasses, to see which are actually present and active during the elimination 
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of A. marginale, would be a way to confirm this theory. 
 
3.4.4. Overall antibody levels and possible link to T-cell function and regulation 
The considerably higher level of IgG production in response to A. centrale infection compared to 
UFMG1 and Gonen is likely to contribute to its success as a vaccine. As previously mentioned, a 
model of immunity against A. marginale suggests a central role for antigen-specific CD4+ T-cells 
and their IFNγ production to stimulate antibody class switching of B-cells, causing high levels of 
IgG production, and in particular increased IgG2 (Palmer et al., 1999). Differences in CD4+ T-cell 
function and their level of IFNγ production, would therefore be a likely candidate to correlate with 
differences in IgG levels between and within groups; investigating this possibility is the subject of 
Chapter 4. A. marginale infection can down-regulate high pre-challenge, recombinant vaccine-
induced CD4+ T-cell responses (Abbott et al., 2005; Han et al., 2008). Han et al. (2008) proposed 
this to be due to deletion of antigen-specific T-cells after overstimulation during infection. This 
phenomenon has not been investigated in A. centrale infection – if it does not occur, this could be a 
central factor behind the higher antibody response seen here in the A.centrale group.  
 
There was a smaller difference in IgG levels between A. marginale strains, with UFMG1 infection 
stimulating lower IgG levels than the Gonen strain. This may be due to UFMG1 being maintained 
in tick cell culture for a number of years before inoculation into the splenectomized calf. Bastos et 
al. (2010) found no significant difference in the level of protection provided by tick cell- or blood-
derived UFMG1, but in that trial tick cell cultures were used less than one year after initialization 
from blood stabilate, as opposed to more than 5 years in this trial. It is possible that prolonged tick 
cell culture may have had an enduring effect on UFGM1 gene expression. For example, MSP1a is 
an important antigen for both cellular and humoral responses (Brown et al., 2001; Palmer and 
McGuire, 1984). A. marginale expresses msp1α at a higher level in blood compared to tick cell 
culture (Garcia-Garcia et al., 2004), and blood-derived A. marginale stimulates higher levels of 
anti-MSPa IgG than tick cell-derived A. marginale (de la Fuente et al., 2002). Therefore if 
prolonged tick cell culture did have a lasting effect on UFMG1 gene expression, the differentially 
expressed proteins in tick cell-derived rickettsia could influence their immunogenicity and 
effectiveness as vaccines.  
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3.4.5. Variation in response to infection 
The level of disease caused by the A. marginale strains and A. centrale varied considerably within 
each group, both during initial infections and after challenge. The severity of symptoms after 
challenge correlated to very variable levels of Anaplasma-specific IgG production during initial 
infection with UFMG1 or A. centrale. A variable response to vaccination against anaplasmosis is 
frequently seen in research studies (Brown et al., 1998; Morse et al., 2012) and in the field (Bock 
and de Vos, 2001), and was suggested by Brown et al. (2003) to reflect genetic differences between 
cattle. This can influence the response to multiple diseases, as can be seen on a large scale by the 
differing susceptibility of Bos indicus and Bos taurus to tick-borne disease (Morris, 2007). 
 
3.4.6. Dynamics of the IgG response to initial infection and challenge 
The association of protection with a reduced secondary IgG response after challenge is interesting, 
as in the classical model of immunity the secondary immune response should be higher and more 
rapid than the primary response (Siegrist, 2012). Live vaccines tend to lead to more prolonged 
antibody responses due to continual exposure to the antigen. But for most calves in this trial there 
was a clear decline in IgG levels after the initial infection, followed by a distinct secondary peak in 
IgG after challenge.  
 
This pattern of higher antibody responses post-challenge being associated with lack of protection 
was also described by Wilson et al. (1980). They noted strong antibody responses to initial infection 
with an Australian A. marginale strain or A. centrale. However, after subsequent challenge with a 
heterologous Australian strain, those calves which were protected from disease showed relatively 
weak secondary rises in antibody level. Barigye et al. (2004) also noted this as occurring after 
successful vaccination with inactivated A. marginale: high antibody titers were induced, which 
dropped after the last inoculation and did not increase again after challenge with live A. marginale. 
 
I would speculate that in protected cattle, the infection is rapidly controlled before it reaches a level 
that would stimulate a strong secondary immune response. In contrast, a lack of protection would 
lead to uncontrolled infection after challenge, which then causes the host immune system to respond 
with a pronounced rise in antibody levels. This model was described for malignant catarrhal fever 
by Russell et al. (2012), and complements the clinical results of this study (see Chapter 2). After 
challenge with the Gonen strain, calves protected from disease had only minimal rises in 
rickettsemia and low to no increase in IgG levels. Presumably the circulating antibodies after initial 
infection were of a sufficient level and specificity to control the infection with the challenge strain 
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before it reached a sufficient level to provoke a strong secondary immune response. In contrast, in 
unprotected animals the circulating antibody was insufficient to contain the infection, and 
rickettsemia increased, triggering a secondary immune response and leading to the high IgG levels 
seen post-challenge. A caveat to this potential explanation is that it does not fit for one calf: after 
challenge this animal (calf #1; UFMG1 group) was PCR-negative for Gonen infection and had no 
symptoms of disease (see Chapter 2) but still had a post-challenge IgG response of a similar level to 
other calves in the group. This case of apparently sterile immunity does not fit the pattern of 
controlled infection leading to lower antibody responses. Unfortunately since sterile immunity 
against anaplasmosis is extremely rare (Kocan et al., 2003), there is no information on the typical 
immune responses in such cases.  
 
3.4.7. Conclusions 
In conclusion, a high, cross-reactive, and IgG2-biased antibody response to initial infection was 
associated with protection after challenge, without a strong secondary IgG response upon challenge 
being necessary.  Prior UFMG1 infection had only a limited protective effect on disease caused by 
the heterologous Israeli Gonen strain. The low pathogenicity of the Israeli Gonen strain in this trial 
makes it impossible to determine if UFMG1 could have reduced fatal disease. However, the limited 
cross-reactivity of the IgG response to UFMG1 suggests that it would also be less protective than A. 
centrale against a more pathogenic challenge strain.  
 
The high levels of cross-reactive IgG induced by A. centrale infection are likely to be a critical 
factor in its success as a vaccine in a wide range of countries. However, further research is needed 
to characterize the factors causing the differing antibody responses, and to determine if these factors 
can be harnessed for other vaccines. 
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CHAPTER 4: CELL-MEDIATED IMMUNE RESPONSE TO 
INFECTION WITH A. MARGINALE OR A. CENTRALE 
 
4.1. INTRODUCTION 
 
4.1.1. Cell-mediated immunity also plays a role in protection from bovine anaplasmosis 
Antibody is an important part of host defence against bovine anaplasmosis (Palmer et al., 1999). 
But several experiments have demonstrated that on its own, antibody is not sufficient to prevent 
disease. Firstly, when persistently infected calves are immunosuppressed by splenectomy (Jones et 
al., 1968) or drugs (Kuttler and Adams, 1977), there is a rapid relapse in symptoms, which begins 
even before circulating antibody levels fall significantly. Secondly, although calves borne to 
immune dams have reduced symptoms compared to those borne to non-immune dams, they are not 
completely protected by colostral transfer of Anaplasma-specific antibodies (Zaugg and Kuttler, 
1984). Finally, serum from a hyper-immune protected steer did not convey passive protection to 
susceptible calves (Gale et al., 1992). Therefore protection against bovine anaplasmosis is not 
solely mediated through humoral immunity.  
 
Multiple studies have shown that cell-mediated immunity also plays a role in the response to 
anaplasmosis. In early experiments, development of protection correlated with inhibition of 
leukocyte migration (Buening, 1976), and with cutaneous hypersensitivity (Carson et al., 1976). 
These results are consistent with a role for T-cells and macrophage activation respectively (Palmer 
et al., 1995).  
 
More specifically, Brown et al. (1998a) demonstrated that after vaccination with A. marginale 
OMPs, protected calves had CD4+ T-cells with high levels of in vitro antigen-specific proliferation 
and IFNγ production. Palmer et al. (1999) proposed that IFNγ produced by CD4+ T-cells might 
play a central role in the immune response to anaplasmosis: by stimulating B-cells to produce high 
levels of IgG2 (Estes et al, 1994; Estes and Brown, 2002), and by activating macrophages to 
increase their phagocytosis and killing of rickettsia (Adler et al., 1994; Stich et al., 1998). Multiple 
T-cell epitopes have been identified in A. marginale MSPs (Brown et al., 1998; Shkap et al., 2002; 
Lopez et al., 2008). However, the majority of A. marginale T-cell research has focused on the 
response to killed, OMP, or recombinant protein vaccines. Studies of the T-cell response to natural 
A. marginale infection suggest that CD4+ T-cells and IFNγ may not play such a central role in the 
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immune response to live vaccines.  
 
4.1.2. Cell-mediated immune responses to live vaccines 
High levels of A. marginale-specific T-cells induced by OMP or recombinant protein vaccination 
fall sharply after infection with live A. marginale (Abbott et al., 2005; Bautista-Garfias et al., 2003; 
Han et al. 2008 and 2010). This reduction in CD4+ T-cell numbers has been proposed to be an 
immune evasion mechanism by A. marginale to facilitate the development of persistent infection 
(Han et al., 2010). Curiously, CD4+ T-cell depletion of thymectomized calves did not prevent them 
from controlling A. marginale infection, and they showed no significant difference in disease 
severity compared to untreated calves (Valdez et al., 2002). There is a caveat to this study, in that 
CD4+ T-cell depletion was not absolute (as this is very difficult to achieve).  
 
Gale et al. (1997) treated four calves with a monoclonal antibody that reduced IFNγ in peripheral 
blood to undetectable levels; there was no significant effect on the severity of their symptoms after 
A. marginale infection. This suggests that IFNγ is not as critical to protection as suggested by 
Palmer et al. (1999), although it is possible that IFNγ could have persisted undetected in treated 
animals, for example in the lymphoid tissues. 
Taken together, these experiments suggest that the T-cell response may not have such a significant 
role in protection with live vaccines as it does with killed, OMP, or recombinant vaccines (Brown et 
al., 1998; Palmer et al., 1999). To date, the T-cell response to the most common live vaccine, A. 
centrale, has been largely unstudied. Gale et al. (1996) found that peripheral blood mononuclear 
cells (PBMCs) from an A. centrale-infected calf proliferated in response to both A. centrale and A. 
marginale antigen preparations. However, this was only one time point from one splenectomised 
calf, taken after antibiotic treatment had reduced the infectious burden. Therefore it is uncertain if a 
more typical A. centrale infection would lead to the reduction in antigen-specific T-cells that is seen 
with A. marginale infection. If the T-cell response to A. centrale is not inhibited, the resulting 
increased 'help' to B-cells (Brown et al., 1998; Grant et al., 2012) could contribute to the higher 
antibody response to A. centrale that was reported in the previous chapter.  
 
4.1.3. Aims 
This chapter describes the measurement of cell-mediated responses, specifically PBMC 
proliferation and IFNγ production, during infection with A. marginale or A. centrale. Any 
relationship to protection from disease would provide an insight into the role of cell-mediated 
immunity in the response to live vaccines against bovine anaplasmosis. 
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4.2. MATERIALS AND METHODS 
4.2.1. Sample collection and processing 
IFNγ levels were measured in plasma: the plasma fraction was taken from blood collected into 
EDTA Vacutainers (Becton Dickinson, Franklin Lakes, New Jersey, USA), then stored at -70 ºC.  
For PBMC purification, blood was collected in a heparin Vacutainer (Becton Dickinson, Franklin 
Lakes, New Jersey, USA).  Blood was diluted 1:1 with PBS, layered carefully over 1.084 g/ml 
Ficoll Premium Plus (GE Healthcare, Uppsala, Sweden) in a 3:1 ratio, and spun at 900 g for 45 
minutes at 18 °C.  The resulting cloudy PBMC layer was carefully collected and washed in PBS to 
remove any remaining Ficoll. Contaminating erythrocytes were lysed by osmotic shock, induced by 
resuspending the cell pellet in 5 ml 10 % PBS for 20s.  45 ml PBS was then added to restore 
osmolarity and the cells washed and resuspended in RPMI 1640 media (Biochrom AG, Berlin, 
Germany).  Cells were counted and either used directly in a proliferation assay, or prepared for 
freezing by resuspension in a freezing media of FBS with 5 % DMSO to a final cell concentration 
of approximately 1x107 cells/ml.  Cryovials were slowly cooled to -70 ºC in a Mr Frosty freezing 
container (Thermo Scientific, Waltham, Massachusetts, USA) for at least 24 hours, before being 
transferred to liquid nitrogen for long-term storage. 
 
4.2.2. PBMC proliferation assays 
PBMCs were either tested directly after isolation from blood (for two time points, one pre- and one 
post-challenge with the Gonen strain) or after cryopreservation (8 time points spread throughout the 
trial). Cryopreserved samples were thawed rapidly in a 37 °C water bath, diluted in RPMI 1640 
media and centrifuged at 500 g for 5 min to remove the DMSO cryopreservative. The pellet was 
resuspended in RPMI 1640, cell concentration and viability measured, and cells resuspended at the 
required final concentration (see Results) for the assay. 
 
Proliferation assays were set up with 2.5 or 5x105 PBMCs per well in a 200 µl total volume, in a 
96-well U-bottom plate (TPP, Trasadingen, Switzerland). Cells and antigen were diluted in RPMI 
1640 supplemented with 10 % FBS, 2 mM L-glutamine, 100 U penicillin / 100 µg/nl streptomycin, 
and 50 µM beta-mercaptoethanol. A. marginale and A. centrale antigen was prepared from infected 
red blood cells or IDE-8 tick cell culture as described in Chapter 3. Cells were incubated with 
antigen at varying concentrations (see Results). The mitogen concanavalin A (ConA; Sigma, 
Munich, Germany) was used as a positive control at 1 µg/ml (fresh PBMCs) or 5 µg/ml 
(cryopreserved PBMCs). Following 6 days incubation at 37 °C and 5 % CO2, bromodeoxyuridine 
(BrdU) (Roche, Mannheim, Germany) at a final dilution of 1:1000 was incubated with cells for a 
76 
further 8 hours. The cells were transferred to a flat-bottomed 96 well plate (TPP, Trasadingen, 
Switzerland), and centrifuged at 300 g for 10 minutes. Supernatants were carefully removed and 
frozen at -70 °C for later testing for IFNγ production. Cells were fixed onto the 96-well plate by 
heating at 60 °C for one hour. A BrdU cell proliferation ELISA (Roche, Mannheim, Germany) was 
used to detect BrdU incorporation into proliferating cells, according to manufacturer’s instructions. 
Final levels of BrdU incorporation were indicated by OD450 absorbance, read by a LEDETECT 96 
plate reader (Labexim Products, Lengau, Austria). 
 
The stimulation index (SI) of different conditions was calculated by:  
OD450 (stimulated cells) ÷ OD450 (media control cells).  
 
4.2.3. IFNγ ELISA 
IFNγ levels were measured using a bovine IFNγ ELISA kit (MABTECH, Nacka Strand, Sweden), 
according to manufacturer’s instructions. Briefly, a high protein binding ELISA plate (Nunc, 
Rochester, NY, USA) was coated with an anti-bovine IFNγ mAb diluted to 2 µg/ml in PBS, and 
plates incubated overnight at 4 °C. They were then washed twice with PBS, and blocked for 1 hour 
at room temperature with diluent (0.05 % Tween20 and 0.1 % bovine serum albumin in PBS). After 
blocking, plates were washed 5 times with wash buffer (0.05 % Tween20 in PBS). Undiluted 
plasma samples or the IFNγ standard (dilution range of 50-500 pg/ml in diluent) were added to 
wells, and incubated for 2 hours. Plates were washed as before, 100 µl of 0.25 µg/ml of a different 
anti-bovine IFNγ mAb in diluent added, and incubated for 1 hour. Plates were washed again, 100 µl 
streptavidin-HRP added (at 1:1000 dilution) and incubated for 1 hour, and washed again. Finally, 
100 µl 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Sigma, Munich, Germany) was added, and 
incubated for 30 minutes, before being stopped by 100 µl 1N HCl. Plates were read at 450 nm with 
a reference wavelength of 690 nm by a LEDETECT 96 plate reader (Labexim Products, Lengau, 
Austria). The results of the IFNγ standard was used to draw a standard curve, from which the IFNγ 
concentration in plasma samples was calculated. 
 
4.2.4. Statistical analysis 
The Minitab software package (Minitab Inc., State College, Pennsylvania, USA) was used for 
statistical analysis. ANOVA and Tukey HSD post-analysis were used to calculate the significance of 
parameter differences between groups (Yandell, 1997). Linear correlations between parameters 
were calculated by the Pearson product-moment correlation coefficient. 
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4.3. RESULTS 
 
4.3.1. Optimization of freezing procedure and PBMC proliferation assay  
To determine the optimum conditions for PBMC cryopreservation, various cell concentrations 
(1x106, 1x107, 1x108 cells/ml) and freezing media (FBS + 5 % DMSO; FBS + 10 % DMSO; horse 
serum + 5 % DMSO) were tested. Freezing cells at 1x107 cells/ml in FBS + 5% DMSO consistently 
gave the best viability and proliferation in response to ConA after thawing (data not shown). 
Therefore this protocol was used for trial samples. 
 
Conditions of the PBMC proliferation assay were optimized, namely: incubation time (4, 5, or 6 
days), cell number (2.5x105 or 5x105 cells/well), assay volume (100 or 200 µl/well), and the effect 
of a resting period between thawing and antigen stimulation. Figure 1 shows the effect of assay 
incubation period on the proliferation of cryopreserved cells in response to 5 µg/ml ConA. Although 
the difference was not significant, 6 days incubation consistently gave slightly higher values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Optimization of incubation period for PBMC proliferation assay with cryopreserved cells. 
A PBMC sample from one calf of each group was used, taken 56 days post-challenge. Similar 
results were seen from cryopreserved naïve cells. Dashed line shows SI=2, the lowest cut-off for 
a positive result.  
There was around a 20 % increase in proliferation in response to 5 µg/ml ConA when 5x105 
78 
cells/well were used rather than 2.5x105 cells/well (data not shown). An assay volume of 200 
µl/well gave consistently higher results than 100 µl (data not shown). A rest period between thawing 
and stimulation of cells did not consistently increase proliferation (data not shown), and so was not 
used. Final conditions for subsequent proliferation assays were therefore set at: no rest period after 
thawing of cryopreserved PBMCs, which were then incubated with antigen or ConA for 6 days, at 
5x105 cells/well in a total volume of 200 µl. 
 
4.3.2. Proliferation of fresh PBMCs 
Fresh PBMCs were tested for antigen-specific proliferation at two time points during the trial: one 
during initial infection shortly before challenge with the Gonen strain, and one 3 weeks post-
challenge. 
 
As the initial infection assay was the first time that immune samples were available to test the 
antigen-specific response to A. marginale, multiple antigen concentrations were used: 1, 5, and 10 
µg/ml. A stimulation index (SI) value of 2 or greater (i.e. at least twice the level of proliferation as 
seen in the media control) was considered a positive result (Brown et al., 1998).  
 
The initial infection assay (8 weeks post-infection) showed all samples were viable and proliferated 
in response to ConA, although often at a relatively low level (data not shown). No proliferation was 
seen in response to A. marginale UFMG1 or A. centrale antigen at 1, 5, or 10 µg/ml (data not 
shown). A. marginale Gonen antigen was not available for testing due to a shortage of infected 
blood pre-challenge (this strain was not established in cell culture until after the trial was 
completed). 
 
Post-challenge PBMCs were tested against UFMG1, A. centrale, and Gonen antigen at higher 
concentrations (10 and 20 µg/ml). Positive proliferation responses were seen in 2 calves of the 
UFMG1 group, 3 calves of the A. centrale group, and all calves of the control group (Figure 2). 
Overall values were still low (SIs of 2-4), but the highest proliferation values were seen in response 
to the Gonen antigen. Of this, the highest SIs were seen in the control group (calves 9-12): at the 
point of testing (pre-patent period of challenge), the control group were the only calves to have 
reached a mean rickettsemia over 0.1 %. However, SI differences between groups were not 
statistically significant. 
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Figure 2: Proliferation response of freshly-
isolated PBMCs in response to A. marginale 
and A. centrale antigen, with samples taken 
3 weeks post-challenge with the Gonen 
strain. (A) UFMG1 group; (B) A. centrale 
group; (C) control group. PBMCs from 
UFMG1 and A. centrale groups were tested 
against 10 and 20 µg/ml of their respective 
homologous strain antigen, and 20 µg/ml 
Gonen strain antigen. PBMCs from the 
control group were tested against 20 µg/ml 
UFMG1, A. centrale, and Gonen strain 
antigens. Dashed line represents SI=2, the 
lowest cut-off for a positive result. 
 
 
 
 
 
 
 
 
 
4.3.3. Proliferation of cryopreserved PBMCs 
Viability of cryopreserved PBMC samples 
PBMC samples were cryopreserved at fortnightly intervals over the course of the trial, and stored in 
liquid nitrogen until transported on dry ice in two batches from Israel to Munich. Samples were then 
stored long-term in liquid nitrogen. On resuscitation of the PBMC samples, cells appeared viable by 
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trypan blue exclusion, but the majority did not proliferate in response to the positive control 
mitogen ConA. For all time points available, a sample from each of the three experimental groups 
was tested. As shown in Figure 3, only two time points showed consistent proliferation in response 
to ConA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Proliferation of cryopreserved PBMCs from different time points throughout the trial, in 
response to the mitogen ConA (5 µg/ml). Cryopreserved PBMCs from one calf per group were 
tested for all time points. Dashed line indicates SI=2, the lowest cut-off for a positive result; the 
arrow indicates point of challenge with Gonen strain, 60 days after initial infection with UFMG1 or 
A. centrale. 
 
 
Analysis of PBMC samples capable of proliferation 
PBMCs from the two time points which showed proliferation in response to ConA were tested 
further for antigen-specific proliferation and IFNγ production. From the proliferation of fresh cells, 
20 µg/ml antigen gave the best results. This was the highest concentration previously tested with 
fresh PBMCs – therefore a range of higher concentrations of Gonen antigen from 20-100 µg/ml 
were tested against cryopreserved samples from 56 days post-challenge (Figure 4). None of the 
concentrations gave a positive proliferative response.  
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Figure 4: Effect of A. marginale Gonen antigen concentration on proliferation of cryopreserved 
PBMCs. PBMCs from one calf per group were tested. Dashed line indicates SI=2, the lowest cut-off 
for a positive result. 
 
Therefore, as it was successful with fresh PBMCs, 20 µg/ml antigen was used for testing all 
samples. Results are shown in Figure 5. The first sample date, 44 days post-challenge (Figure 5.A.), 
showed a low level of antigen-specific proliferation for 2 calves of the UFMG1 group. The second 
sample date, 56 days post-challenge (Figure 5.B.), had no calves with detectable antigen-specific 
PBMC proliferation.  
 
Proliferation in response to ConA varied considerably between different calves, and between the 
two time points. Several calves had only very low levels of proliferation after ConA stimulation, 
and one calf (from the 44 day post-challenge time point) even gave a negative result (i.e. SI < 2).  
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Figure 5: Proliferation of 
cryopreserved PBMCs post-
challenge in response to  
A. marginale Gonen antigen.  
(A) 44 days post-challenge.  
(B) 56 days post-challenge. Dashed 
line indicates SI=2, the lowest cut-off 
for a positive result. 
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4.3.4. IFNγ production in vitro and in vivo 
 
4.3.4.1. In vitro IFNγ production in antigen stimulation assays 
 
IFNγ production by fresh PBMCs 
IFNγ production by fresh PBMCs (Figure 6) in response to antigen or ConA was high - however, 
PBMCs incubated with media alone also produced high levels of IFNγ. The IFNγ levels in media 
controls were higher than in the A. marginale Gonen samples for almost all calves, and also higher 
than the ConA positive control for two calves. There was no significant correlation between IFNγ 
production and PBMC proliferation.  
 
 
 
 
 
 
 
 
 
Figure 6: IFNγ production by fresh PBMCs 3 
weeks post-challenge. (A) UFMG1 group, (B) A. 
centrale group and (C) Control group calves. 
Similar results were seen with the antigen 
stimulation assay using PBMCs from the initial 
infection (data not shown). 
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IFNγ production by cryopreserved PBMCs 
The two sample dates which had PBMCs capable of responding to the mitogen ConA were tested 
for IFNγ production. There was very variable IFNγ production between calves, with no significant 
correlation to proliferation, and on average, cryopreserved PBMCs produced lower levels of IFNγ 
than fresh PBMCs. There was no significant difference in IFNγ production between UFMG1, A. 
centrale and control groups for either of the two post-challenge sample dates (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: IFNγ production by cryopreserved PBMCs post-challenge in response to 20 μg/ml A. 
marginale Gonen antigen. (A) 44 days post-challenge. (B) 56 days post-challenge. 
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4.3.4.2. IFNγ levels in vivo during initial infection and challenge 
IFNγ levels were measured in plasma samples taken over the course of initial infection with A. 
marginale UFMG1 or A. centrale, and after subsequent challenge with A. marginale Gonen (Figure 
8). 
 
 
 
 
 
 
 
 
Figure 8: IFNγ levels over the course of 
initial infection and challenge.  
(A) UFMG1 group,  
(B) A. centrale group,  
(C) control group.  
Arrow indicates point of challenge with 
the Gonen strain, at 2 months after 
initial infection with UFMG1 or  
A. centrale.  
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UFMG1 and A. centrale infection induced different patterns of IFNγ production, with peak IFNγ 
levels in UFMG1-infected calves being significantly higher (p<0.05). Calves in both groups showed 
low levels of IFNγ during the first month, only slightly elevated above the background level of 
uninfected calves. However, in the second month of infection, IFNγ levels remained low in A. 
centrale-infected calves (around 50 pg/ml), but rose steeply in 3 out of 4 UFMG1-infected calves, 
to peaks of 100, 200, and 400 pg/ml respectively. Calf #1 of the UFMG1 group, which was PCR-
negative for the Gonen strain after challenge, was one of these calves, peaking at 100pg/ml IFNγ. 
 
After all calves were challenged with the Gonen strain, calves from both the UFMG1 and A. 
centrale groups had a similar response, with two out of four calves from each group showing steep 
and very high rises in IFNγ. The two UFMG1 group calves which had the highest response to initial 
infection with UFMG1 (#2 and #4) did not show a second peak in IFNγ after challenge, although 
their IFNγ responses to the initial UFMG1 infection persisted at levels considerably above 
background. The calf which had a lower IFNγ peak of 100 pg/ml during UFMG1 infection (#1) had 
returned to background IFNγ levels shortly after challenge, and subsequently had a higher 
secondary peak in IFNγ (550 pg/ml) at around 40 days post-challenge. There was no statistically 
significant difference in peak IFNγ levels post-challenge in UFMG1 and A. centrale group calves; 
both were significantly higher than peak IFNγ levels in the control group (p<0.05). 
 
Calves in the control group, which were solely infected with A. marginale Gonen, showed very 
little IFNγ response post-challenge. In the 2 months of measurement post-challenge, only one calf 
showed a rise above background levels, peaking at around 100 pg/ml. The post-challenge IFNγ 
response was therefore considerably higher in previously infected calves than in calves solely 
infected with the Gonen strain. 
 
Plasma samples for IFNγ testing were taken approximately every 7 days. The majority of high IFNγ 
responses were relatively transient; four out of the six calves which had levels of 100 pg/ml only 
registered these high responses at one or two time points tested. Two calves - both in the UFMG1 
group - were an exception to this, with one having IFNγ levels that remained at over 100 pg/ml for 
more than a month. 
 
Association of IFNγ levels and clinical parameters  
Higher levels of IFNγ (>100 pg/ml) were generally seen late in infection – consequently they were 
usually after the most severe symptoms (the period of maximum rickettsemia, maximum fever, or 
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minimum hematocrit) had passed. Therefore when IFNγ concentrations in plasma samples were 
compared to clinical parameters from the same time points, there were no significant correlations 
between IFNγ concentration and rickettsemia, hematocrit, or temperature (data not shown). 
 
For each calf, the maximum IFNγ level measured over the course of infection was compared with 
the overall severity of symptoms they showed (maximum rickettsemia, maximum temperature, 
minimum hematocrit). There was a significant correlation (p<0.05, data not shown) between the 
magnitude of the IFNγ response during initial infection with UFMG1 or A. centrale, and the 
corresponding maximum rickettsemia and minimum hematocrit. This was largely due to UFMG1 
infection, which had both more severe symptoms and higher IFNγ levels during infection. However, 
post-challenge with the Gonen strain, there was no statistically significant relationship between 
IFNγ and any of the clinical parameters. 
 
Association of IFNγ levels and other immunological parameters  
IFNγ enhances the production of IgG2 by bovine B-cells (Estes and Brown, 2002). Therefore IFNγ 
levels in plasma were compared to the ratio of IgG1: IgG2. There was no significant correlation 
between IFNγ levels and IgG1:IgG2 during initial infection, but a strongly significant correlation 
between the two parameters during challenge with A. marginale Gonen (p<0.02). As shown in 
Figure 9, the higher the IFNγ levels in plasma during challenge, the greater the bias towards an 
IgG2 response. 
 
 
Figure 9: Correlation between 
maximum post-challenge IFNγ 
levels and IgG1:IgG2(r=-0.62; 
p<0.02). An IgG1:IgG2 ratio 
of one or greater implies an 
IgG1 bias; a ratio of less than 
one implies an IgG2 bias. 
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4.4. DISCUSSION 
 
4.4.1. PBMC proliferation 
A. marginale infection has been reported to lead to a fall in levels of antigen-specific T-cells (Abbott 
et al., 2005; Han et al., 2008 and 2010). Therefore it was not unexpected that this trial found no or 
low levels of PBMC proliferation in response to UFMG1, A. centrale or Gonen antigen.  
 
Some antigen-specific proliferation was seen post-challenge from fresh and cryopreserved PBMCs. 
However, there was no significant difference in levels of PBMC proliferation between the UFMG1, 
A. centrale, or control groups. This suggests that the greater protection seen after the A. centrale 
live vaccine was not due to a stronger T-cell response. However, this hypothesis cannot be firmly 
rejected on the basis of this trial, as there were multiple issues with the scope and reliability of the 
PBMC data. 
 
Firstly, there was extremely limited data on PBMC proliferation from calves infected with only A. 
marginale UFMG1 or A. centrale – i.e. using samples taken before challenge. The PBMC response 
to this initial infection would be likely to play a very important role in subsequent protection from 
later challenge: through T-cell amplification of the IgG response (Grant et al., 2012), and through 
the development of pre-activated T-cells which can respond more rapidly upon challenge 
(Zinkernagel and Hengartner, 2006).  
 
Unfortunately, cryopreserved PBMCs from pre-challenge time points were non-viable. For fresh 
PBMCs, only one assay was performed prior to challenge, at 8 weeks post-infection, since purified 
antigen was not available any earlier. Unfortunately, by 8 weeks post-A.marginale infection, any T-
cell response is likely to be waning (Bautista-Garfias et al., 2003). In addition, this assay used a 
very low antigen concentration. 10 µg/ml was the highest concentration tested; the subsequent post-
challenge assay tested 10 and 20 µg/ml, and found that generally only 20 µg/ml induced PBMC 
proliferation. Therefore it is likely that the antigen concentration used in the pre-challenge PBMC 
assay was too low to stimulate any antigen-specific T-cells present.  
 
The second, and main problem, with the in vitro PBMC data is that the PBMC assay protocol was 
insufficiently optimized. As there was no prior access to A. marginale-infected cattle, only the 
response to ConA and cryopreservation conditions could be tested before the trial began. During the 
trial, a limited number of assays were done with freshly-isolated PBMCs. The bulk of optimization 
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and testing was intended to be done with cryopreserved cells, prepared from time points throughout 
initial infection and challenge. This would allow simultaneous testing of multiple time points 
against antigens from all strains, for a more valid comparison of results. As described in the next 
section, this was unfortunately not possible.  
 
More assay optimization should have been done with fresh cells early in the infection, and these 
optimized conditions used to test fresh PBMCs from more time points. Although this would have 
meant fewer samples could have been cryopreserved, it would have allowed a much better 
assessment of the response from fresh PBMCs. Since freshly isolated cells are more sensitive to 
antigenic stimulation (Weinberg et al., 1998), any negative proliferation results could be more 
confidently assumed to genuinely reflect the in vivo response, rather than being a possible result of 
experimental shortcomings.  
 
Cryopreserved PBMCs 
Cryopreserved PBMCs were transported by air from Israel to Munich, on dry ice in two separate 
flights. All samples were checked on arrival in Munich, appeared to still be frozen, and were stored 
in liquid nitrogen for later analysis. Only PBMC samples from the second flight were capable of 
proliferating in response to ConA, a very strong inducer of T-cell proliferation. As samples from the 
two batches were otherwise treated identically, there may have been an issue with the transportation 
of the first batch of PBMCs. However, as all samples appeared to still be frozen after transport, 
there is no clear explanation for why the PBMCs from the first batch were not capable of 
proliferating.  
 
An unexpectedly low response to ConA was seen in multiple cryopreserved PBMC samples, and in 
fresh PBMCs from both infected and uninfected calves. As this low proliferation was seen in 
PBMC samples from uninfected calves, it is unlikely to be general immunosuppression as a result 
of the infection, as seen with A.phagocytophilum (Whist et al., 2003). It may instead be due to 
shortcomings in the PBMC purification protocol or in the assay itself. Low proliferation in response 
to ConA, an extremely strong mitogen, makes it less likely that any antigen-specific proliferation 
would be high enough to measure. 
 
To conclude, the PBMC data is of very limited value due to shortcomings in the experimental 
design of assays with fresh cells (assays were too few, too late, and insufficiently optimized), and in 
the sample transport of cryopreserved PBMCs (which prevented many time points from being 
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tested). Therefore it is impossible to draw any firm conclusions from this data about the relative 
strength of the A. marginale and A. centrale T-cell proliferation response, and its role in protection 
from anaplasmosis. 
 
4.4.2. IFNγ production by PBMCs 
The caveats on interpretation of PBMC proliferation data previously discussed also affect the data 
on in vitro IFNγ production by PBMCs. There was an additional aspect which was curious: freshly 
isolated PBMCs produced high levels of IFNγ in media control samples. This could have been due 
to cross-contamination from other samples during the IFNγ ELISA, but this would be unlikely to 
cause such consistently high levels of IFNγ in so many samples. It could be genuine reaction by 
PBMCs in response to a component of the media used. However, the high reaction to media was not 
seen in cryopreserved samples, which used an identical media recipe. It is possible that the different 
batches of FCS used for fresh and cryopreserved PBMCs could be responsible for different 
background levels of IFNγ.  
 
This adds more data to the overall conclusion that the results from isolated PBMCs, whether fresh 
or frozen, cannot be used to draw any firm conclusions on the cell-mediated immune response to A. 
marginale and A. centrale. 
 
4.4.3. In vivo IFNγ levels during A. marginale and A. centrale infection 
In his model of vaccine-induced immunity to A. marginale, Palmer et al. (1999) proposed a central 
role for the cytokine IFNγ. This pro-inflammatory cytokine has a wide range of effects, as reviewed 
in Schroder et al. (2004). Most critically for the response to anaplasmosis, IFNγ plays a role in the 
humoral immune response by stimulating B-cells to produce IgG2 (Estes et al, 1994; Estes and 
Brown, 2002). It also activates macrophages, leading to increased levels of antigen presentation and 
phagocytosis, and a greater ability to kill phagocytosed microbes (Stich et al., 1998; Adler et al., 
1994).  
 
Several studies have detected in vitro IFNγ production by PBMCs in response to A. marginale 
antigen (Brown et al., 1998; Bautista-Garfias et al., 2003; Barigye et al., 2004). However, only two 
studies have measured in vivo IFNγ levels during A. marginale infection (Bautista-Garfias et al., 
2003; Nazifi et al., 2012). Bautista-Garfias et al. (2003) experimentally inoculated 1-year-old cattle 
and measured IFNγ over the course of acute infection. But as they did not quantify IFNγ levels 
beyond arbitrary ELISA units, IFNγ concentrations cannot be closely compared with this trial. 
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Nazifi et al. (2012) did quantify IFNγ levels, and found considerably lower IFNγ concentrations 
than seen here. In that study, infected cattle had average IFNγ levels of 0.5 pg/ml. In this trial, the 
average peak IFNγ concentration in infected cattle was 180 pg/ml, over 300 times higher. However, 
Nazifi et al. (2012) measured adult cattle with a naturally-acquired persistent infection. In this trial, 
calves were sampled during acute infection when IFNγ levels are likely to be at their highest, and 
the number of infectious units used here to inoculate the calves is likely to be considerably higher 
than the low levels passed on during natural infection (Pacheco et al., 2004).  
 
In this trial, many peaks of IFNγ were very briefly seen - for most calves higher IFNγ levels were 
measured in one or two time points only. Prolonged high levels of IFNγ without immune control 
would lead to prolonged inflammatory responses, which would be likely to damage the host (Martin 
et al., 2001) However, the brevity of cytokine responses combined with relatively infrequent 
sampling means that it is possible that IFNγ peaks could have been missed in some calves if high 
IFNγ levels did not correspond to a sampling point.  
 
With that caveat, there was a higher IFNγ response to UFMG1 infection than to A. centrale 
infection. However, the IFNγ peaks were seen late in UFMG1 infection, and so are unlikely to have 
contributed to the more severe symptoms caused by the UFMG1 strain. High IFNγ responses seen 
only late in infection (from 51 days post-infection) was also reported by Bautista-Garfias et al. 
(2003). The IFNγ response to UFMG1 was also significantly higher than the naïve response to 
Gonen infection (i.e. IFNγ in the control group post-challenge). As UFMG1 and Gonen infections 
produced similar levels of anemia, it confirms that IFNγ production does not directly relate to 
pathology (Gale et al., 1996).  
 
After challenge with Gonen, calves previously infected with UFMG1 or A. centrale showed a 
higher IFNγ response than the naïve control group. In the case of two calves of the A. centrale 
group, this high post-challenge response was despite not having a high IFNγ response to initial A. 
centrale infection. This suggests that T-cell responses primed during initial infection produced a 
considerably amplified secondary response on re-exposure. A higher IFNγ response on re-infection 
compared to initial A. marginale infection was also seen by Bautista-Garfias et al. (2003).  
 
During challenge with the Gonen strain, higher IFNγ levels were significantly associated with an 
IgG2-biased antibody response. This was not unexpected, as it has been previously demonstrated in 
vitro that IFNγ stimulates bovine B-cells to produce high levels of IgG2 (Estes et al., 1994). 
92 
Curiously, during initial infection with UFMG1 or A. centrale, there was no such clear association:  
surprisingly A. centrale infection stimulated the highest IgG2 bias despite a low IFNγ response. The 
regulation of IgG subclass expression is complex (Estes and Brown, 2002), and it is likely that other 
factors beyond IFNγ are responsible for the higher IgG2 production in A. centrale infection.  
 
Higher IgG2 is associated with protection from anaplasmosis (Brown et al., 1998; Barigye et al., 
2004; Vega et al., 2007; see Chapter 3). Therefore it would be interesting to investigate some of the 
other factors potentially responsible for the higher IgG2 expression after A. centrale infection – for 
example, interferon alpha or TGF-beta, which in vitro can also stimulate IgG2 production from B-
cells (Estes et al., 1998).  
 
Because IFNγ has been proposed as central to protection from anaplasmosis (Palmer et al., 1999), 
previous vaccine studies have tried to stimulate high IFNγ production in vaccinees. Tuo et al. 
(2000) used an IL-12 adjuvant with a recombinant MSP2 vaccine, and successfully stimulated high 
levels of IFNγ in three calves. However, only one of these calves produced detectable antigen-
specific IgG2 – and this was the calf with the lowest level of IFNγ. 
 
Clearly the regulation of the antibody response to A. marginale infection is too complex to simply 
aim for a vaccine which stimulates high levels of IFNγ. In this trial the immune response to A. 
centrale was significantly more protective than the response to UFMG1, despite stimulating lower 
IFNγ production. The successful development of future vaccines could be helped considerably by 
investigating which other factors lie behind A. centrale infection stimulating the higher IgG level 
and greater IgG2 bias seen in this study.  
 
4.4.4. Conclusion 
No solid conclusions could be drawn from the in vitro PBMC proliferation and IFNγ production 
data. The in vivo IFNγ data showed that previous infection with UFMG1 or A. centrale leads to 
amplified IFNγ production on subsequent challenge with the Gonen strain. This amplified post-
challenge IFNγ response correlates with higher levels of IgG2. But other factors beyond IFNγ 
appear to also have a role in enhancing IgG2 production, as seen in A. centrale infection, and should 
be further investigated.  
 
It has been proposed that the role of IgG2 in protecting cattle from anaplasmosis is the effectiveness 
of IgG2 in enhancing phagocytosis (Palmer et al., 1999). Studies have previously demonstrated that 
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immune sera against A. marginale have opsonophagocytic activity (Cantor et al., 1993; Melendez et 
al., 2005). However, neither of these studies investigated if the opsonophagocytic activity was 
actually related to IgG2 levels, or more importantly, correlated with protection from disease. 
Developing a functional assay to determine this information will be the subject of the next chapter. 
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CHAPTER 5: OPSONOPHAGOCYTIC ACTIVITY OF IMMUNE 
SERA AGAINST A. MARGINALE 
 
5.1. INTRODUCTION 
 
5.1.1. The value of measuring antibody function as a correlate of protection 
All antibodies are not created equal. Even if an antibody binds to a pathogen, it will not necessarily 
have a protective effect against disease (Plotkin 2008). Antibodies have three main functions against 
pathogens: neutralization, opsonization, and bactericidal activity. Different antibodies vary in their 
effectiveness at these functions. Therefore while ELISAs are a simple and practical tool to measure 
the immunogenicity of a vaccine, an assay for antibody function may correlate better with 
protection (Johnson et al., 1999).  
 
Functional antibody assays are used to assess vaccines against many diseases. For example, it was 
found that for mice infected with Streptococcus pneumoniae, the opsonophagocytic activity of their 
serum samples was a better indicator of protection than IgG titers (Johnson et al., 1999). 
Standardized in vitro opsonophagocytosis assays are now often used to assess the performance of 
pneumococcal vaccines (Romero-Steiner et al., 2006). Serum bactericidal activity is used to assess 
vaccines against Neisseria meningitidis (Plotkin et al., 2008), and growth inhibition assays are used 
in malaria vaccine research (Bergmann-Leitner et al., 2006).  
 
Therefore the functional activity of antibodies can be an excellent and useful correlate of protection 
to measure.  Correlates of protection can identify which immune mechanisms are most important 
against different diseases, which guides further vaccine development. They also provide a useful 
alternative to challenge trials, especially if these are dangerous or logistically difficult (Plotkin et 
al., 2008). While challenge trials for Anaplasma marginale are relatively straightforward in 
endemic areas, establishing good correlates of protection would be very useful in estimating the 
effect of vaccines against a wider range of strains than it would be practical to challenge cattle with. 
 
5.1.2. Opsonophagocytosis as a correlate of protection for bovine anaplasmosis 
IgG2 levels induced by inactivated or recombinant protein vaccines correlated with protection from 
anaplasmosis in several studies (Brown et al., 1998; Barigye et al., 2004; Vega et al., 2007). Palmer 
et al. (1999) proposed that the importance of IgG2 in reducing the symptoms of anaplasmosis was 
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due to its effectiveness in opsonising bacteria, leading to better clearance of A. marginale by 
phagocytic cells.  
 
In cattle, both IgG1 and IgG2 can fix complement and mediate phagocytosis; however, IgG2 is 
considerably more rapid and effective at enhancing phagocytosis by neutrophils and peripheral 
blood monocytes (McGuire et al., 1979; McGuire and Musoke, 1981).  
 
Opsonophagocytosis has been demonstrated in vitro with immune sera and A. marginale by Cantor 
et al. (1993) and Melendez (2005). However, neither of these studies investigated if the 
opsonophagocytic activity (OPA) was actually related to IgG2 levels, or more importantly, whether 
OPA correlated with protection from disease. These theories could be tested by using an 
opsonophagocytosis assay to test serum samples from the live vaccine trial described in Chapter 2, 
and comparing results to severity of disease (Chapter 2) and levels of IgG2 (Chapter 3). 
 
5.1.3. Measuring opsonophagocytosis 
Many in vitro assays have been developed to measure opsonophagocytosis. These assays either 
detect the uptake of micro-organisms or other targets, the killing of micro-organisms, or the 
production of reactive oxygen species (ROS) (Lehmann et al., 2000). Phagocytic cells use ROS, 
which include nitric oxide (NO), superoxide anion (O2-), and hydrogen peroxide (H2O2), to kill the 
micro-organisms they have engulfed. The production of these ROS is known as the respiratory burst 
or oxidative burst, and is stimulated by phagocytosis. The ingestion of micro-organisms causes the 
phagocytic cell to assemble the multi-subunit enzyme NADPH oxidase. Once assembled, NADPH 
oxidase converts molecular oxygen to O2-, which is further converted by other enzymes to produce 
a range of toxic ROS (reviewed by Bylund et al., 2010). 
 
The simplest but most subjective method for measuring phagocytosis is by microscopy. A 
conventional microscope can be used to see phagocytosed objects inside Giemsa-stained cells 
(Melendez 2005), or to see the nitroblue tetrazolium precipitation products which form on contact 
with ROS (Park et al., 1968). A fluorescent microscope can be used to more reliably visualize 
intracellular bacteria when they are either stained directly with a fluorescent dye or tagged with a 
fluorochrome-conjugated antibody (Cantor et al., 1993). While microscopy is very useful for small-
scale studies, it has disadvantages: it is highly labor-intensive and time-consuming, and can be 
subjective – results are likely to vary from operator to operator (Chaka et al., 1995).  
 
99 
Phagocytosis can also be tested through measuring the killing of target micro-organisms. After 
incubating the target with phagocytic cells, the level of killing is assessed either by plating out 
samples after the assay (Leijh et al., 1979), level of [3H]-thymidine uptake (White and Walker, 
1981), or viability indicator dyes (Goldner et al., 1983). Batch-to-batch variation in the initial 
viability and growth rate of the bacterial stocks used in these assays can easily affect the results 
(Hampton et al., 1999).  
 
There is a range of more high-throughput and reliably quantifiable methods. Chemiluminescence 
assays rely on the fact that the oxidative burst results in electronically excited oxidation products – 
when these relax back to their ground state it leads to photon emission. Adding luminol or lucigenin 
boosts the photon emission to the point that the chemiluminescence can be detected and quantified 
by a luminometer (Allen 1977). Chemiluminescence is a highly sensitive method to quantify 
phagocytosis, but reagents vary in effectiveness between different cell types, and the signal can be 
easily affected by any contaminating red blood cells (Kopprasch et al., 2003; Easmon et al., 1980). 
 
Currently, flow cytometry is possibly the most high-throughput, objective, and flexible method for 
measuring phagocytosis. It is fast, so large numbers of samples can be measured. Within each 
individual sample, information from tens of thousands of cells can be collected, so it is considerably 
more objective than microscopy, in which limited numbers of cells can be counted (Lehmann et al., 
2000). It can be used to measure bacterial uptake, level of killing, or ROS production. 
 
The uptake of bacteria can be measured by staining them with a fluorophore. This can be done by 
using an antigen-specific fluorescent-tagged antibody, but binding of the tagged antibodies may 
then inhibit immune sera from binding to relevant epitopes (Lehmann et al., 2000). A more efficient 
alternative is to use fluorescent dyes which integrate into the nucleic acid or the cell membrane of 
bacteria.  
 
The oxidative burst resulting from phagocytosis can be measured by indicator dyes. These dyes are 
incubated with and taken up by phagocytic cells; if these cells then phagocytose a micro-organism 
and trigger the oxidative burst reaction, the indicator dye will fluoresce when it reacts with the 
oxidative burst ROS products. Examples of these indicator dyes are hydroethidine, xylenol orange, 
dichloro-dihydro-fluorescein diacetate (DCFH-DA), and the widely used and extremely sensitive 
dihydrorhodamine 123 (DHR123) (Vowells et al., 1995; Lehmann et al., 1997). DHR123 is non-
fluorescent, but converts to fluorescent rhodamine 123 in the presence of ROS (Rothe et al., 1988).
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Over the past few decades, opsonophagocytosis assays have become increasingly more objective, 
easier to standardize, and more high-throughput. Therefore they have become an increasingly 
practical tool for assessing samples from vaccine trials. 
 
5.1.4. Aims 
Antibodies are important in protection against bovine anaplasmosis, and due to the association of 
higher IgG2 levels with protection, opsonophagocytosis has been proposed as an important 
mechanism of antibody action against A. marginale. There is evidence that immune sera against A. 
marginale have opsonophagocytic activity (OPA), but no evidence to date that OPA correlates with 
IgG2 levels, or with protection against anaplasmosis. 
 
Both studies on opsonophagocytosis and A. marginale to date have used microscopy. While this is a 
very effective method, it is time-consuming and subjective, and therefore of limited use when 
testing large numbers of samples from vaccine trials.  
 
The aim of this chapter is therefore the development of a high-throughput, practical and objective 
opsonophagocytosis assay for A. marginale, which could in future serve as a more efficient tool for 
vaccine assessment. This assay will be used to measure the sera from the live vaccine trial of A. 
marginale UFMG1 and A. centrale reported in previous chapters. The OPA of serum from calves in 
the trial will be compared with the calves' corresponding clinical symptoms, IgG production, and 
IFNγ levels, to help build up a picture of the role of opsonphagocytosis in protection against bovine 
anaplasmosis. 
 
 
5.2. MATERIALS AND METHODS 
 
5.2.1. Sera 
Sera were taken from calves infected with A. marginale or A. centrale as described in Chapter 3, 
aliquoted and stored at -80ºC until used.  
 
5.2.2. Bacteria 
Purification of bacteria 
A. marginale Gonen strain bacteria were purified from IDE-8 tick cell culture as described in 
Chapter 3. The quantity of bacteria was estimated by RT-PCR, after the method of Carelli et al. 
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(2007). Briefly, DNA was extracted from bacteria with the QIAamp DNA Mini Kit (Qiagen, 
Germany), and tested in an msp1b RT-PCR (protocol described in Chapter 2) alongside a quantified 
msp1b plasmid standard. The standard was produced as described by Lis et al. (manuscript 
submitted):  an A. marginale msp1b gene fragment was cloned into the pGEM®-T easy vector 
(Promega, Medison, USA), propagated into competent Escherichia coli cells, and plasmids purified 
with QIAprep Spin Miniprep Kit (Qiagen, Germany). The msp1b copy number was then calculated 
from the OD of the purified DNA. 
 
Staining of bacteria 
For some experiments, bacteria were labeled with nucleic acid stains. The nucleic acid stain SYTO9 
(Invitrogen, Darmstadt, Germany) has an optimum excitation wavelength of 485 nm and emission 
wavelength of 498 nm. It is membrane-permeable, and so is taken up by viable and non-viable cells. 
SYTO9 was tested at concentrations from 50 nM – 20 µM, diluted in Dulbecco's PBS (DPBS). 100 
µl bacteria were added to an equal volume of SYTO9 (at double the final concentration of dye), and 
incubated, shaking, for 30 minutes at room temperature. After incubation, any free dye was 
removed by washing samples six times (spinning at 16000 g for 5 minutes), and the pellet of 
bacteria re-suspended in 100 µl DPBS. 
 The nucleic acid stain propidium iodide (PI) (Invitrogen, Darmstadt, Germany) has an optimum 
excitation wavelength of 535 nm and emission wavelength of 617 nm. It is membrane impermeable 
and therefore generally only taken up by non-viable cells with compromised membranes. Therefore 
before staining, bacteria were killed by incubation with 1 % formaldehyde, 70 % ethanol, or at 56 
°C heat (all for 1 hour, followed by washing once at 16000 g for 5 minutes). Bacteria were then 
stained with 50-200 µg/ml PI, using the same procedure as described for SYTO9, but with an 
incubation period of 1 hour. 
 
5.2.3. Cell preparation 
Separation of leukocytes 
Blood was collected into heparin Vacutainers (Becton Dickinson, Franklin Lakes, New Jersey) from 
the jugular vein of adult Fleckvieh cattle (Bos taurus), spun at 1000 g for 15 minutes, and the 
plasma fraction removed. The remaining cell fraction was treated to lyse erythrocytes: 1 volume of 
cells was mixed with 2 volumes of 0.02 M NaCl for 30 seconds, and osmolarity restored by 
addition of 0.5 volumes 0.164 M NaCl. The leukocytes remaining were spun at 400 g for 5 minutes, 
and washed twice in 5 mM glucose in DPBS (DPBS-G) to remove the debris of lysed erythrocytes. 
Cells were then resuspended in 10 ml DPBS-G, counted, and finally resuspended at 2x106 cells/ml 
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in DPBS-GCM assay buffer (5 mM glucose, 1.2 mM CaCl2, 1 mM MgSO4 in DPBS). 100 µl of 
cells were added to 96-well microtiter plates (TPP, Trasadingen, Switzerland), and incubated at 38 
°C, 5 % CO2 for 2 hours before use in the assay. 
 
Staining of leukocytes 
For some experiments, the leukocytes were stained with dihydrorhodamine 123 (DHR123) 
(Invitrogen, Darmstadt, Germany). 5 µl of 400 µg/ml DHR123 was added to 100 µl cells in the 
microtiter plate, for a final DHR123 concentration of 20 µg/ml. The plate was then incubated 
shaking for 5 minutes to allow cells to take up the dye before being used in the phagocytosis assay.  
 
5.2.4. Assay set-up 
Bacteria were diluted to required concentration (see Results) in DPBS-GCM assay buffer. 10 µl 
diluted bacteria and 10 µl serum were added to a 96-well microtiter plate. Serum samples were 
tested in duplicate. Sufficient assay buffer was added to each well to bring the total volume to 50 µl, 
and samples mixed by pipetting. The plate was then sealed with an air-permeable film (Sigma, 
Munich, Germany) and incubated at 38 °C, 5 % CO2 for one hour to allow antibodies to bind to 
bacteria. After one hour, 50 µl of cells were added to the wells (cells unstained or after 5 minutes 
staining with DHR123), and the plate re-incubated at 38 °C for 15-45 minutes (see Results). The 
assay was stopped by addition of ice-cold DPBS + 0.02 % EDTA.  
 
5.2.5. Flow cytometry 
Samples were read using a MACSQuant VYB flow cytometer (Miltenyi Biotec, Bergisch Gladbach, 
Germany). For each sample, 100 µl was read, containing approximately 25000 cells. DHR123 and 
SYTO9 were both excited by a 488 nm laser, with fluorescence collected by a 525/50 nm bandpass 
filter. A 561 nm laser was used to excite PI, with resulting fluorescence collected by a 615/20 nm 
bandpass filter.   
 
Flow cytometry data were analyzed using Weasel® software (Walter and Eliza Hall Institute of 
Medical Research, Victoria, Australia). Doublets and clumps were excluded from analysis by gating 
on FSC-A vs. FSC-H. Granulocytes were then selected by their size and density (FSC-A vs. SSC-
A). Fluorescence in this population was then taken as the level of phagocytosis.  
 
To ensure that the threshold for positive events (i.e. cells which had phagocytosed bacteria) was set 
consistently between assays, the threshold gate was set in every assay to include 10 % of cells in the 
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fluorescence histogram of the cell only control. This gate was then applied to all test samples, and 
level of phagocytosis quantified as the fluorescence index (FI): % cells gated x mean intensity of 
gated cells (Li et al., 2006). 
 
5.2.6. Statistical analysis. 
The Minitab software package (Minitab Inc., State College, Pennsylvania, USA) was used for 
statistical analysis. ANOVA and Tukey HSD post-analysis were used to calculate the significance of 
parameter differences between groups (Yandell, 1997). Linear correlations between parameters 
were calculated by the Pearson product-moment correlation coefficient. 
 
 
5.3. RESULTS  
 
5.3.1. Using bacterial staining to measure opsonophagocytosis 
Testing nucleic acid dyes 
Two nucleic acid dyes, SYTO9 and propidium iodide (PI), were tested for their efficacy in staining 
A. marginale. 
 
SYTO9 successfully stained bacteria. However, when these stained bacteria were incubated with 
leukocytes, sufficient dye leached from the bacteria that the nucleus of the leukocytes also became 
stained (assessed by fluorescence microscopy, data not shown). This was despite six wash steps – 
any further washing reduced the numbers of bacteria too much to be practical. 
PI also successfully stained bacteria, and when these PI-stained bacteria were incubated with 
leukocytes, no dye transferred to the cell nuclei (data not shown). Therefore the PI staining protocol 
was optimized further for use in the opsonophagocytosis assay.  
 
PI is only taken up by non-viable cells with compromised membranes. When A. marginale bacteria 
were stained directly after being purified from tick cell culture, many did not pick up the dye 
(assessed by fluorescence microscopy, data not shown). This agrees with results from Lis et al. 
(manuscript submitted) that Percoll gradient-purified rickettsia retain a high level of viability. 
Several killing methods were investigated to improve the uptake of PI, namely: heat killing, 
ethanol, and formaldehyde (see Materials and Methods). Heat killing and ethanol caused the 
bacteria to clump, which made it more difficult to add a standardized number of bacteria to each 
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well. Formaldehyde did not have this problem, and increased the percentage of bacteria which were 
successfully stained (data not shown). 
 
Formaldehyde-killed bacteria stained with PI were tested in an in vitro opsonophagocytosis assay. 
Leukocytes were incubated for 30 minutes with stained bacteria, which were either untreated or had 
been pre-incubated with immune sera. As shown in Figure 1, leukocytes alone had a very low level 
of background fluorescence. When stained, untreated bacteria were added, only low numbers of 
bacteria were taken up or attached to the cells – as shown by a small increase in numbers of 
fluorescent cells. The addition of immune sera opsonized the bacteria, leading to considerably 
increased phagocytosis or attachment – shown by increased numbers of fluorescent cells and higher 
intensity of fluorescence (the latter indicating greater numbers of bacteria taken up by or attached to 
each leukocyte).  
 
Figure 1: Overlay histograms of the increase of leukocyte fluorescence after incubation with PI-
stained bacteria (untreated or pre-incubated with immune sera). 
 
 
Determining Attachment vs. Uptake 
When phagocytic cells bind bacteria, the bacteria may be phagocytosed, or may remain attached to 
the surface of the cell rather than being fully internalized and killed. Therefore it is important to 
ensure that phagocytosis assays only measure fully internalized bacteria (Hed, 1986).  
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The simplest way to compare levels of internalized vs. attached bacteria is to run the same 
phagocytosis assay in parallel at the physiological temperature of the cells, and at a lower 
temperature. At physiological temperature, cells will be active and able to internalize bacteria. At 
the lower temperature, any internalization should be negligible, and so any fluorescence from the 
cells can be attributed to bacteria which are only attached to the outside of the cell (Hed, 1986; 
Giunta et al., 2008). 
 
PI-stained bacteria were tested in the OPA assay at 38 ºC (bovine physiological temperature) and 4 
ºC, with results shown in Figure 2. The fluorescence at 38 ºC was only around 30 % higher than the 
fluorescence seen at 4 ºC – indicating that the majority of the signal in this assay at 38 ºC is likely to 
be from attached rather than internalized bacteria.  
Figure 2: Results of the OPA assay using PI-stained bacteria at 4 ºC and 38 ºC. C+B = Cells + 
Bacteria. C+B+IS = Cells+Bacteria+Immune sera. 
 
 
5.3.2. Using the oxidative burst to measure opsonophagocytosis 
DHR123 is a non-fluorescent substrate which converts to fluorescent rhodamine-123 in the 
presence of ROS. Therefore when cells are stained with DHR123, their level of fluorescence 
becomes an indicator of the level of the oxidative burst response. As the oxidative burst is triggered 
by phagocytosis (Bassoe et al., 2000), using DHR123 in an opsonophagocytosis assay removes the 
need to distinguish attachment from internalization.  
 
106 
DHR123-stained leukocytes were incubated for 30 minutes with bacteria alone, or with bacteria 
pre-incubated with immune sera. As shown in Figure 3, there was some background fluorescence 
for cells alone. When untreated bacteria were added, there was a small increase in fluorescence. The 
addition of bacteria pre-incubated with immune sera led to considerably increased fluorescence – 
indicating a much higher uptake of opsonized bacteria and subsequently higher level of oxidative 
burst by the leukocytes. Therefore an OPA assay using DHR123-stained leukocytes was developed 
further. 
Figure 3: Overlay histograms of the increase in fluorescence of DHR123-stained leukocytes after 
incubation with bacteria (untreated or pre-incubated with immune sera). 
 
5.3.3. Defining and analyzing the in vitro phagocytosis assay 
The two most abundant groups of phagocytic cells are mononuclear phagocytes (monocytes and 
macrophages) and polymorphonuclear granulocytes (Silva, 2010). Lymphocytes may also show a 
very low level of phagocytosis from B-cells (Sunyer, 2012).  
 
The leukocytes used in the opsonophagocytosis assay contained granulocytes, monocytes, and 
lymphocytes. The gating strategy to analyse these cells is shown in Figure 4. First, in Figure 4.A., 
single cells were selected, as any doublets would give a disproportionately high fluorescent signal. 
Then different cell populations were identified on the basis of their differing size and granularity. 
Figure 4.B. shows the phagocytic activity of the different cell types. In this assay, lymphocytes 
showed no detectable phagocytic activity and monocytes only a very low level. Only the 
granulocyte population showed clearly measurable phagocytic activity. Therefore further work on 
the opsonophagocytosis assay was based only on the fluorescence signal from the granulocyte 
population. 
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Figure 4: Gating strategy to determine which cell populations showed increased oxidative burst 
activity when incubated with bacteria and immune sera.  
(A) Initial gating strategy of selecting single cells based on FSC-A vs. FSC-H, then identifying 
distinct cell populations based on size (FSC-A) vs. granularity (SSC-A). 
(B) Level of oxidative burst in different cell populations. Only granulocytes showed a clear increase 
in fluorescence with the addition of opsonized bacteria. 
 
When DHR123-stained cells phagocytose bacteria, there are an increased number of fluorescent 
cells, and an increase in the intensity of their fluorescence. In order to capture both of these 
properties, the results of the opsonophagocytosis assay are expressed as the Fluorescence Index 
(FI). The FI is calculated from percentage of fluorescent cells multiplied by the mean intensity of 
their fluorescence. Therefore it incorporates both the percentage of cells which phagocytose the 
target, and the level of phagocytosis within those cells. The calculation of FI is shown in Figure 5.  
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Figure 5: Calculating the fluorescence index (FI). (A) cell only control, showing 10% gate (shaded 
population), and formula for calculation of fluorescence index (FI). (B) Test samples, showing the 
increased % of cells gated and the increased intensity of fluorescence with the addition of bacteria 
and sera. (C) Histogram of FI values for samples shown in (A) and (B). 
 
Figure 5.A. shows the cell only control.  The cut-off for background fluorescence needed to be 
standardized between assays to compensate for inter-assay differences in flow cytometer settings 
and cell activity. Therefore the fluorescence gate on the cell only control is set to include 10% of the 
cells. Any cells showing fluorescence levels beyond this gate are counted as positive events, and 
included in the calculation of FI (see Figure 5.A.). Figure 5.B. shows histograms from test samples 
showing increased fluorescence with the addition of bacteria, which are either untreated or pre-
incubated with immune or non-immune sera. The FI values of the samples in Figure 5.A. and 5.B 
are shown in Figure 5.C. 
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5.3.4. Optimization of the opsonophagocytosis assay 
The conditions of the OPA assay were optimized to maximize the difference between the FI of 
immune sera (IS) and the background signal. 
 
First, DHR123 concentrations from 5-20 μg/ml were tested. As shown in Figure 6, 20 μg/ml 
DHR123 gave the greatest separation between the 'bacteria only' and the 'bacteria and immune sera' 
samples. Therefore this concentration was used for future assays. 
 
Figure 6: effect of DHR123 concentration on level of OPA measured. C=cells only, 
C+B=cells+bacteria, C+B+IS=cells+bacteria+immune sera. 
 
 
The primary incubation period - when bacteria and sera were combined - was kept constant at one 
hour. The secondary incubation period - after leukocytes were added - was varied, and 15, 30, and 
45 minute incubation periods were tested for several bacteria:cell ratios (Figure 7).  
 
FI increased with the length of secondary incubation - with a sharp increase from 15 to 30 minutes, 
and then a lower increase from 30 minutes to 45. For all bacterial concentrations tested, a secondary 
incubation time of 45 minutes gave the greatest difference between the FI of bacteria with immune 
sera and control condtions (bacteria alone or with non-immune sera). The highest bacteria:cell ratio 
tested, 6200:1, gave the best results.
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Figure 7: Effect of the length of OPA assay secondary incubation period and bacterial 
concentration on FI.  C+B=cells+bacteria, C+B+IS=cells+bacteria+ non-immune sera, C+B+IS 
= cells+ bacteria+immune sera. 6500, 2500, or 1500 bacteria per cell were tested. 
 
The ratio of bacteria per cell is critically important for the level of oxidative burst (Anding et al., 
2003), and so was tested in more detail. Accurately quantifying the bacteria purified from tick cell 
culture was problematic. As the A. marginale rickettsia are very small, reliably distinguishing them 
from co-purified tick cell mitochondria by an optical microscope was difficult, and an electron 
microscope was not available. Therefore the concentration of bacteria was estimated by a 
quantitative PCR targeting A. marginale msp1b (see Methods).  
 
The oxidative burst response at different bacteria:cell ratios is shown in Figure 8. The response to 
immune sera increased rapidly with bacteria:cell ratio from 200 bacteria per cell up to 800 bacteria 
per cell, and then showed small and inconsistent increases as bacterial numbers increased further. 
The ratio with the greatest separation between the FIs of immune and non-immune sera was 3250 
bacteria per cell.
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Figure 8: Effect of different 
bacteria:cell ratios on the 
differentiation between OPA of 
immune sera and non-immune sera. 
The double-headed arrow indicates 
ratio with greatest differentiation 
between immune serum and non-
immune serum samples (3250 
bacteria per cell). 
 
 
 
One complete 96-well microtiter plate took approximately two hours for all samples to be analyzed 
by flow cytometry. To determine whether the time of reading would make a significant difference in 
the fluorescent signal, replicates of an IS and NIS sample was tested at approximately hourly 
intervals over a three-hour period (Figure 9). The non-immune sample showed no change over the 
three hours; the immune sample showed a gradual but non-significant increase in FI. 
 
Figure 9: The effect of read-time on the fluorescence of immune (IS) and non-immune (NIS) 
samples. 
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Therefore the final optimum conditions of the assay were 20 μg/ml DHR123 used to stain cells, 
which were then incubated with bacteria for 45 minutes at a bacteria:cell ratio of 3250:1. No more 
than one full 96-well microtiter plate was used in any assay to prevent the slight increase in signal 
over time from influencing the results. 
 
5.3.5. Testing serum samples from the live vaccine trial against A. marginale Gonen 
The optimized assay conditions were used to measure the OPA of serum samples from the live 
vaccine trial described in Chapter 3. The challenge strain in the trial, A. marginale Gonen, was used 
as the target of the OPA assay.  
 
A comparison of the OPA against the Gonen strain that was induced by infection with UFMG1, A. 
centrale or Gonen strain is shown in Figure 10. The average OPA response to A. centrale was 
higher than to UFMG1 or Gonen infection, but the difference was not significant. 
 
 
Figure 10: Opsonophagocytic activity induced 
by infection with UFMG1, A. centrale or 
Gonen. Results for Gonen infection were taken 
from the control group post-challenge. 
Horizontal bars indicate the median for each 
group. 
 
 
 
 
 
 
The maximum OPA results for each calf during initial infection, and after challenge with the Gonen 
strain, are shown in Figure 11. Three out of four calves infected with UFMG1 showed very similar 
OPA levels during initial infection with UFMG1 and challenge with Gonen. This contrasts with IgG 
levels in the UFMG1 group (see Chapter 3), which rose sharply after challenge.  
 
OPA levels for calves infected with A. centrale showed similar dynamics for overall IgG levels and 
OPA levels. Three out of four calves showed a higher OPA response to initial infection with A. 
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centrale than to challenge with Gonen. 
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Figure 11: OPA of sera during 
initial infection and challenge, for 
the UFMG1 group (calves 1-4), A. 
centrale group (calves 5-8), and 
control group (calves 9-12).  
 
 
 
 
 
5.3.6. Comparing OPA levels to clinical symptoms, IgG2, and IFNγ 
 
Correlations between OPA and clinical symptoms 
During initial infection with UFMG1 or A. centrale, higher OPA correlated significantly with milder 
disease symptoms – specifically with a lower temperature (p<0.02), less reduction in hematocrit 
(p<0.01), and a lower rickettsemia (p<0.01), as shown in Figure 12. 
 
Figure 12: Correlations between OPA and clinical symptoms during initial infection with UFMG1 
or A. centrale. From left to right, graphs show maximum OPA compared to (A) maximum 
temperature, (B) maximum reduction in hematocrit, and (C) maximum rickettsemia per calf, over 
the course of initial infection. 
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When the maximum level of OPA found in sera during initial infection was compared to the clinical 
response to challenge, high pre-challenge OPA correlated significantly (p<0.01) with less severe 
post-challenge anemia (see Figure 13). There was no such correlation with temperature or 
rickettsemia. 
 
 
 
Figure 13: Correlation between pre-challenge OPA and 
post-challenge reduction in haematocrit (r = -0.81, 
p<0.01). 
 
 
 
 
 
Correlations between OPA and other immunological parameters 
Levels of OPA were compared to levels of total IgG, IgG2, and IFNγ during initial infection with 
UFMG1 or A. centrale and challenge with the Gonen strain. When OPA was compared with the 
IFNγ concentration, there was no significant correlation during initial infection or challenge. During 
initial infection with UFMG1 or A. centrale, OPA did show significant correlations with IgG1: IgG2 
ratio (p<0.06), total IgG2 concentration (p<0.1), and increase in IgG (p<0.05) as shown in Figure 
14. Considering the period after challenge with the Gonen strain in isolation, there was no 
significant correlation between OPA levels and IgG parameters.  
 
Figure 14: Correlations between OPA during initial infection with UFMG1 or A. centrale and (A) 
IgG1:IgG2, (B) IgG2 concentration, and (C) fold change in IgG.
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5.4. DISCUSSION 
 
5.4.1. Measuring phagocytosis through the uptake of fluorochrome-stained bacteria 
Initially, the OPA assay was intended to detect phagocytosis by measuring the uptake of 
fluorochrome-stained bacteria. This was found to be impractical as an unsuitably high proportion of 
the fluorescent signal came from extracellular bacteria attached to the outside of phagocytic cells.  
 
Extracellular fluorescence can be reduced by a quenching agent, which absorbs the fluorescence of 
any bacteria remaining outside the cell. Trypan blue is the most common quenching agent, as it will 
not enter living cells and so will not quench the fluorescence of any internalized bacteria (Bjerknes 
and Bassoe, 1984). Unfortunately the absorption spectrum of trypan blue does not fully cover the 
emission spectra of PI, and initial experiments found it to be ineffective in quenching PI 
fluorescence. SYTO9, the other nucleic acid dye which was tested, can be quenched by trypan blue, 
but had problems with the dye leaching from stained bacteria. The leaching of SYTO9 might be 
reduced by formaldehyde fixation of the stained bacteria, but unfortunately fixation decreases 
fluorescence emission for SYTO dyes (Lebaron et al., 1998).  
 
5.4.2. Measuring phagocytosis through the oxidative burst 
The final OPA assay measured phagocytosis by detecting the level of oxidative burst. Within the 
mixed leukocyte population that was used, only the data from granulocytes was analyzed. This was 
because they were the only population to show a clear increase in oxidative burst when incubated 
with opsonized bacteria. The relatively low oxidative burst response from the monocyte population 
is likely to be due to the long incubation time in the in vitro assay. Bassoe et al. (2000) found that 
after more than 5 minutes incubation with the target, ROS production by monocytes began to 
decrease. In contrast, ROS production from granulocytes increased with longer incubation periods.  
 
When comparing the ROS production of monocytes and granulocytes, van Pelt et al. (1996) and 
Bassoe et al. (2000) found that monocytes produced some ROS even without phagocytosis. In 
contrast, granulocytes required phagocytosis to trigger ROS production. Therefore analyzing data 
from granulocytes provides a reassurance that analysing the oxidative burst response will not 
overestimate the level of phagocytosis. 
 
The optimum bacteria:cell ratio found here - 3250 bacteria per cell - was extremely high in 
comparison to other in vitro OPA assays. Cantor et al. (1993) used 50 A. marginale per macrophage. 
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The method used in that study to quantify bacteria was very approximate, based on percentage of 
infected erythrocytes before rickettsia were purified. However assays with other targets also used 
similar numbers: Vogel et al. (1994) used 10 Haemophilus influenzae for every cell, and Bassoe et 
al. (2000) 40-60 opsonin-coated beads.  
 
It is likely that the 3250 bacteria per cell calculated here considerably over-estimated the actual 
number of intact bacteria per cell. The rtPCR quantification method used here provides a way to 
compare different batches of bacteria, but it is very likely to overestimate the number of bacteria 
that will be effective targets in the OPA assay. Epitopes on the surface of the bacteria must be intact 
for them to be opsonized by immune serum; with qPCR, DNA from broken up or damaged bacteria 
will also be counted.  
 
It would be valuable to improve quantification methods for A. marginale to be used in in vitro 
assays. At present, numbers of purified bacteria are often simply estimated from the percentage of 
infected cells in the original blood sample or tick cell culture. Unfortunately as rickettsia are so 
small, it is very difficult to count them accurately once they are purified. Quantifying them by flow 
cytometry, using a nucleic acid stain such as SYTO9, or an  A. marginale-specific antibody and then 
a fluorescent-tagged secondary antibody, could be considerably more accurate, but their propensity 
for clumping would still add a degree of uncertainty to the final count. 
 
Vaccine trials often produce large numbers of samples which should if possible be tested 
simultaneously to allow for a more valid comparison of results. Therefore in this OPA assay, the 
slight increase in fluorescence when samples are read at a later time point could be problematic 
when larger numbers of samples have to be analyzed. This increase in fluorescence may be able to 
be reduced by formaldehyde fixing of samples, but this can often alter the results of oxidative burst 
assays (C. Brookes, personal communication). More accurate results with a smaller number of 
samples were therefore preferable. 
 
The OPA assay could be further improved, for example: finding an effective bacterial stain would 
allow the simultaneous measurement of phagocytosis and oxidative burst. Access to a heated plate 
mixer would be likely to reduce both the number of bacteria and the incubation time required for 
the assay (Hampton et al., 1999), saving time and resources. Nevertheless, overall the OPA assay 
developed here is effective, and allows the analysis of up to 42 duplicated samples per assay. It is 
considerably faster and more objective than the equivalent OPA assays using microscopy, and 
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therefore more useful in assessing the functional antibody response to A. marginale vaccines. 
 
5.4.3. OPA response to A. marginale and A. centrale infection 
During infection with UFMG1 or A. centrale, a higher level of OPA correlated with milder clinical 
symptoms. A stronger OPA response to these initial infections also correlated with a reduced anemia 
upon subsequent challenge with the Gonen strain. There was a lack of correlation between OPA 
levels after challenge and the severity of symptoms – possibly, because as proposed in Chapter 3, a 
strong antibody response to initial infection may control the challenge infection before it can reach 
a level that provokes a strong new immune response. 
 
Overall, these results corroborate the theory of Palmer et al. (1999) that OPA plays an important 
role in clearing A. marginale and protecting cattle from anaplasmosis. The model of Palmer et al. 
(1999) was based on studies showing that IgG2, the IgG subclass that is most effective at 
opsonization, has repeatedly been linked to protection (Chapter 3; Brown et al., 1998; Barigye et 
al., 2004; Vega et al., 2007), and that immune sera can opsonize A. marginale (Cantor et al., 1993; 
Melendez 2005).  
 
The two previous studies of opsonophagocytosis with A. marginale confirmed that it occurs but 
could not determine whether it correlated with protection. Cantor et al. (1993) demonstrated that 
sera from calves immunized with purified MSP-1 significantly increased the phagocytosis of A. 
marginale by bovine macrophages. They tested sera samples from five calves, and found 
statistically significant differences in OPA activity of their sera. However, as all the calves used 
were completely protected from challenge after immunization (Palmer et al., 1989), it was not 
possible to determine if the differences in OPA correlated with level of protection from challenge. 
 
Melendez (2005) demonstrated that immune serum could opsonize A. marginale-infected red blood 
cells, but as the sera used came from only one acutely infected and one immunized calf it was 
impossible to infer the importance of OPA in reducing disease symptoms. 
 
Therefore this is the first study that explicitly demonstrated an association of OPA with reduced 
disease symptoms, confirming and expanding on considerable supporting evidence from previous 
studies (summarized in Palmer et al., 1999). 
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5.4.4. The relationship of OPA to other immune parameters 
A significant correlation was seen between IgG2 concentration and OPA levels during infection 
with UFMG1 or A. centrale. This was expected, as several studies have shown that IgG2 is 
considerably more rapid and effective than IgG1 at enhancing phagocytosis by neutrophils and 
peripheral blood monocytes (McGuire et al., 1979; McGuire and Musoke, 1981). 
 
In the model of opsonophagocytosis by Palmer et al. (1999), IFNγ played an important role in 
activating macrophages to increase their level of phagocytosis. However in this trial, serum IFNγ 
concentration did not significantly correlate with OPA levels. This is perhaps not surprising as the 
assay here measured OPA in granulocytes, which are largely neutrophils (Murphy et al., 2012). 
Although neutrophils can be activated by IFNγ (Marchi et al., 2014), as 'first-responder' cells, they 
are more involved in producing IFNγ than in responding to it (Kumar and Sharma, 2010). 
 
5.4.5. Conclusions and Future Research 
Overall, OPA appears to be a useful correlate of a protective immune response to A. marginale. The 
relatively high-throughput in vitro OPA assay developed here could be very useful in estimating the 
effect of candidate vaccines against a wider range of strains than it would be practical to challenge 
cattle with.  
 
More specialized OPA assays could also be used as a tool to investigate the immune response to A. 
centrale in more detail. Identifying antigens recognized by IgG2 from A. centrale-immunized cattle 
has already been used to find novel target proteins for vaccine research (Agnes et al., 2011). The 
reasoning behind this study was that IgG2 is associated with protection due to its central role in 
OPA (Palmer et al., 1999). But the opsonophagocytic activity of serum is not solely determined by 
IgG2 titer – other factors such as antibody avidity also play a role (Johnson et al., 1999). An OPA 
assay could be used to more directly identify which proteins are targeted by functional antibodies. 
Coating microsphere beads with recombinant protein antigens allows individual proteins to be 
evaluated for their importance as a target of the functional antibody response (Lehmann et al., 
1997). This technique has been used for assessing meningococcal (Lehmann et al., 1999; Plested et 
al., 2001) and streptococcal (Fabrizio et al., 2010) antigens. Applied to A. centrale, this would be a 
valuable screening tool for identifying more effective vaccine candidates. 
 
At the more basic level used here, the OPA assay provided an effective and relatively 
straightforward technique for evaluating serum samples from the live vaccine trial. A. centrale 
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infection induced higher levels of OPA in calves than UFMG1 infection. The higher OPA 
corresponded to a greater level of protection from disease on challenge with the heterologous 
Gonen strain. This further supports the evidence from the previous chapters that A. centrale induces 
a more effective immune response than UFMG1, enabling it to be a significantly more effective live 
vaccine.  
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6. GENERAL CONCLUSIONS  
 
 
6.1. Rationale for the Project 
 
The aim of this project was to investigate the immune response to live vaccines against bovine 
anaplasmosis. A. centrale, the current 'gold-standard' live vaccine, was compared with UFMG1, a 
naturally low pathogenic Brazilian A. marginale strain, which has been proposed as a potentially 
safer cell culture-derived live vaccine. Calves were premunised with A. centrale or UFMG1, before 
being challenged with the heterologous Israeli A. marginale Gonen strain. The immune response of 
the calves was then compared with their level of protection from disease. This study therefore 
evaluated UFMG1 as a live vaccine, and elucidated correlates of protection from bovine 
anaplasmosis to help guide future vaccine development. 
 
6.2. Main Findings of the Project 
Chapter 2 described the trial comparing the effectiveness of A. centrale and A. marginale UFMG1 
in protecting calves against the Israeli A. marginale Gonen challenge strain. A. centrale was 
significantly more effective than UFMG1 at reducing disease symptoms after challenge. UFMG1 
was proposed as a potential live vaccine against A. marginale by Bastos et al. (2010), because it 
successfully protected calves from a heterologous and high pathogenic Brazilian A. marginale 
strain. Unfortunately, UFMG1 was not as effective when tested against a Israeli A. marginale strain. 
After challenge with the Israeli Gonen strain, anaplasmosis symptoms in calves previously infected 
with UFMG1 were similar to those in the naïve calves of the control group. In addition, UFMG1 
infection itself caused a concerning level of disease symptoms, approaching close to the threshold 
for antibiotic treatment. The young calves used in the trial were the age group least affected by A. 
marginale infection. This suggests that the use of UFMG1 as a live vaccine is highly likely to cause 
problems in the field, where mechanical and biological transmission from vaccinated calves to more 
vulnerable adult cattle is always a possibility.  
 
Chapter 3 investigated the serological response induced by A. centrale and A. marginale UFMG1. 
A. centrale infection induced a higher level of IgG, with a greater bias to IgG2, and also showed 
more cross-reactivity to antigen from the Gonen challenge strain. The IgG2 concentration, and level 
of IgG cross-reactivity to the challenge strain correlated significantly with subsequent protection 
from challenge.  
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Chapter 4 investigated the cell-mediated response to A. centrale and A. marginale UFMG1 – 
namely levels of PBMC proliferation and IFNγ production. No consistent antigen-specific PBMC 
proliferation was seen in samples from either group. However, there were numerous problems with 
the PBMC proliferation assays, which made it impossible to draw any firm conclusions from these 
experiments. When in vivo IFNγ concentrations were measured, previous infection with UFMG1 or 
A. centrale resulted in amplified levels of IFNγ production after challenge with Gonen. This 
amplified post-challenge IFNγ response correlated with higher levels of IgG2, associated with 
protection from challenge. However, other factors beyond IFNγ appear to also have a role in 
enhancing IgG2 production, as during initial A. centrale infection there was a low IFNγ response 
but high IgG2 concentrations. 
 
Chapter 5 described the development of an in vitro assay for serum opsonophagocytosis activity 
(OPA) against A. marginale. The OPA assay was based on flow cytometric measurement of the 
oxidative burst response to phagocytosis. OPA has previously been suggested as a correlate of 
protection for bovine anaplasmosis, but this had not been experimentally confirmed. In this study, 
calves which had higher OPA in their antibody response to initial infection were better protected 
from subsequent challenge with the heterologous Gonen strain. As expected, serum samples with 
higher IgG2 concentrations showed higher levels of OPA. Taken in combination with previous 
studies, these results suggest that OPA is an effective correlate of protection against bovine 
anaplasmosis. 
 
Overall, this study showed that A. centrale was considerably more effective as a live vaccine than 
UFMG1, as only premunisation with A. centrale effectively protected calves against disease. 
Several characteristics of the serological response to premunisation significantly correlated with 
reduced disease upon subsequent challenge with Gonen: a high and cross-reactive IgG response, an 
IgG2 bias, and high OPA levels. A. centrale was more effective at consistently inducing this type of 
protective immune response than UFMG1. 
 
The current model for a protective immune response against bovine anaplasmosis is largely based 
on studies from recombinant protein vaccination (Palmer et al., 1999). However, these vaccines are 
so far confined to research trials, with live vaccination being the most effective approach in the 
field. From the results of this project, it appears that are likely to be differences in the mechanisms 
by which protein vs. live vaccination lead to protection from anaplasmosis. 
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The model of protection after protein vaccination proposed by Palmer et al. (1999) centers around 
antigen-specific CD4+ T-cells and their production of IFNγ, which activates macrophages and 
stimulates B-cells to produce more IgG2. Antigen-specific IgG2 opsonises A. marginale, leading to 
increased phagocytosis by the activated macrophages and control of the infection.  
 
However, during infection with A. marginale, there is large-scale selective deletion of Anaplasma 
antigen-specific CD4+ T-cells (Han et al., 2010). Despite this removal of the CD4+ T-cells, calves 
which survive infection with A. marginale are generally well protected against homologous strains 
(Bock  et al., 2001). Therefore it seems unlikely that CD4+ T-cells can play such a central role in 
immunity induced by live vaccination.  
 
The data on the T-cell response to live vaccination from this project was inconclusive, but other 
aspects of Palmer’s model appear to still apply here, namely, the correlation of IgG2 and 
opsonophagocytic activity with protection. However, the vast majority of phagocytic activity was 
seen from granulocytes, rather than macrophages as proposed by Palmer.  
 
It is possible that granulocytes may be even more important in protection against anaplasmosis, as 
neutrophils can fulfil several of the functions that were assigned to CD4+ T-cells in Palmer’s model. 
These functions are centralized in the spleen, which has been shown to be critical for controlling A. 
marginale infection (Jones et al., 1968). Once neutrophils have phagocytosed circulating bacteria, 
they transport them to the marginal zone of the spleen (Balázs et al., 2002). Splenic neutrophils then 
serve as helpers for marginal zone B-cells: these B-cells specialize in rapidly producing T-cell 
independent antibody responses to blood-borne micro-organisms (Puga et al. 2011). The splenic 
neutrophils stimulate B-cell survival, antibody production, class switching, and somatic 
hypermutation. As neutrophils produce IFNγ (Etuin et al., 2004), they can bias the antibody 
response towards production of IgG2, with its greater opsonic activity. Therefore, there is the 
intriguing possibility that the CD4+ T-cells central to Palmer’s model - but deleted during A. 
marginale infection - could have their role in protection at least partially filled by neutrophils. 
 
6.3. Future Research 
Many trials of A. marginale vaccines use homologous challenge strains, which is an excellent initial 
step to test candidate vaccines. But one of the main problems with existing A. marginale vaccines is 
the lack of cross-protection between the highly diverse strains. This was seen here again with 
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UFMG1, which was protective against a heterologous Brazilian strain (Bastos et al., 2010), but not 
against the more distantly related Israeli strain used in this study.  
 
Testing candidate vaccines against a wide range of heterologous strains is an important part of 
evaluating their potential. But performing challenge trials against multiple strains can be 
prohibitively expensive, taking considerable time and resources. Reliable correlates of protection 
that can be measured in vitro would be a valuable method for gauging the potential cross-protection 
induced by candidate vaccines.  
 
The results here confirm previous studies that IgG2 appears to be a good correlate of protection, and 
show for the first time that the OPA of the immune response to live vaccines also correlates 
significantly with later protection from challenge. The in vitro OPA assay developed here has the 
potential to be used to test immune serum samples against a range of A. marginale strains, and to 
identify specific antigens targeted by the functional antibody response. 
 
Previous infection with UFMG1 did not significantly reduce the severity of disease after challenge 
with the heterologous Gonen strain, whereas A. centrale did provide cross-protection. As seen here, 
A. centrale infection led to high production of IgG, high cross-reactivity within that IgG response, a 
strong IgG2 bias, and high opsonophagocytic activity. All of these characteristics are likely to be 
important factors behind the widespread success of the A. centrale vaccine.  
 
Understanding how A. centrale infection stimulates this effective immune response would be a 
valuable direction for future vaccine research. This could either be through identifying protective 
antigens, to suggest a more rational design of a subunit vaccine; or by determining critical cytokines 
induced by A. centrale infection, which could suggest suitable adjuvants to add to vaccine 
formulations. 
 
A. centrale has some problems as a vaccine: safety concerns due to it being derived from blood, and 
reports of failure against high pathogenic strains. However, A. centrale is still used extensively and 
successfully in many countries. Possibly the most practical and cost-effective approach to 
developing a better anaplasmosis vaccine would be to focus research on making the A. centrale 
vaccine safer and more consistently able to induce the type of protective immune response 
identified here. 
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7. APPENDIX: SUMMARY OF CLINICAL AND 
IMMUNOLOGICAL DATA 
 
Initial infection 
 
Group Calf 
Peak 
rickettsemia 
(% iRBCs) 
Peak 
temperature 
(°C) 
Minimum 
PCV (% 
pcv) 
Reduction 
in PCV (% 
pcv) 
% 
Reduction 
in PCV 
A. marginale 
UFMG1 1 7.00 39.50 21.00 7.00 25.00 
 
2 8.00 40.00 21.00 11.00 34.38 
3 14.00 40.00 18.00 20.00 52.63 
 
4 11.00 40.00 19.00 16.00 45.71 
Median 9.5 40.0 20.0 13.5 40.0 
A. centrale 5 1.00 39.10 33.00 -4.00 -13.79 
 
6 8.00 39.50 23.00 13.00 36.11 
 
7 8.00 40.30 21.00 16.00 43.24 
8 3.00 39.40 27.00 5.00 15.63 
 
Median 5.5 39.5 25.0 9.0 25.9 
Control 9 0.00 39.70 29.00 7.00 19.44 
 
10 0.00 39.00 31.00 0.00 0.00 
 
11 0.00 39.10 30.00 4.00 11.76 
 
12 0.00 40.10 28.00 10.90 28.02 
  Median 0.0 39.4 29.5 5.5 15.6 
 Post-challenge with A. marginale Gonen 
 
Group Calf 
Peak 
rickettsemia 
(% iRBCs) 
Peak 
temperature 
(°C) 
Minimum 
PCV (% 
pcv) 
Reduction 
in PCV (% 
pcv) 
% 
Reduction 
in PCV 
A. marginale 
UFMG1 1 0.01 41.20 23.00 5.00 17.86 
 
2 7.00 39.70 19.00 13.00 40.63 
 
3 3.00 40.80 20.00 18.00 47.37 
 
4 0.50 39.70 24.00 11.00 31.43 
 
Median 1.8 40.3 21.5 12.0 36.0 
A. centrale 5 1.09 40.50 29.00 0.00 0.00 
6 0.02 41.30 32.00 4.00 11.11 
 
7 0.09 39.30 30.00 7.00 18.92 
 
8 3.00 39.40 22.00 10.00 31.25 
 
Median 0.6 40.0 29.5 5.5 15.0 
Control 9 4.00 40.10 22.00 14.00 38.89 
 
10 0.70 39.40 20.00 11.00 35.48 
 
11 7.00 40.10 20.00 14.00 41.18 
12 0.50 39.60 26.00 12.90 33.16 
  Median 2.4 39.9 21.0 13.5 37.2 
Table 1: Summary of clinical data (see chapter 2 for further information). 
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Initial infection 
Group Calf 
Max. IgG   
(fold 
change) 
Max. IFNγ 
(pg/ml) IgG1:IgG2 
Max. IgG2 
(µg/ml) 
OBA 
activity 
A. marginale UFMG1 1 2.34 117.47 1.39 33.93 1.83E+06 
 
2 3.05 221.18 1.21 107.47 1.42E+06 
3 2.41 47.65 1.08 60.27 9.80E+05 
 
4 2.15 434.36 1.21 64.00 8.81E+05 
 
Average 2.49 205.16 1.22 66.42 1.28E+06 
Std Dev 0.39 168.61 0.13 30.47 4.38E+05 
A. centrale 5 6.66 35.17 0.53 246.55 2.59E+06 
 
6 4.47 82.29 0.74 168.16 1.75E+06 
7 2.84 58.07 1.59 11.29 1.42E+06 
 
8 2.47 34.37 2.55 3.61 1.51E+06 
 
Average 4.11 52.47 1.35 107.40 1.82E+06 
Std Dev 1.91 22.71 0.92 119.81 5.34E+05 
Control 9 1.20 37.33 1.81 3.53 1.22E+05 
 
10 1.11 21.97 1.74 3.53 1.26E+05 
11 1.04 15.89 1.75 3.64 1.19E+05 
 
12 1.89 26.83 1.75 3.32 1.21E+05 
Average 1.31 25.51 1.76 3.51 1.22E+05 
  Std Dev 0.39 9.07 0.03 0.13 2.92E+03 
 Post-challenge with A. marginale Gonen 
Group Calf 
Max. IgG   
(fold 
change) 
Max. IFNγ 
(pg/ml) IgG1:IgG2 
Max. IgG2 
(µg/ml) 
OBA 
activity 
A. marginale UFMG1 1 4.69 552.78 0.55 240.02 1.46E+06 
 
2 5.03 79.96 1.06 563.07 1.41E+06 
3 4.55 487.65 0.95 185.11 1.08E+06 
 
4 8.54 395.66 0.82 600.39 1.16E+06 
 
Average 5.70 379.01 0.85 397.15 1.28E+06 
Std Dev 1.90 209.53 0.22 214.85 1.87E+05 
A. centrale 5 5.30 552.78 1.07 250.84 2.02E+06 
 
6 3.57 21.76 2.55 30.50 1.33E+06 
7 2.01 552.92 2.01 58.07 9.35E+05 
 
8 3.18 11.73 2.47 62.36 1.60E+06 
 
Average 3.51 284.80 2.03 100.44 1.47E+06 
Std Dev 1.36 309.55 0.68 101.25 4.56E+05 
Control 9 4.83 12.45 1.28 109.32 1.00E+06 
10 2.76 13.09 2.11 29.37 1.23E+06 
11 4.10 90.32 0.94 175.57 1.97E+06 
 
12 5.36 7.66 1.80 105.42 1.88E+06 
Average 4.26 30.88 1.53 104.92 1.52E+06 
  Std Dev 1.13 39.70 0.52 59.77 4.77E+05 
Table 2: Summary of immunological data (see Chapters 3,4, and 5 for further details). 
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8. ABBREVIATIONS 
 
B  Bacteria 
BrdU  Bromodeoxyuridine 
C  Cells 
C3R  C3 complement protein receptor 
C4R  C4 complement protein receptor 
ConA  Concanavalin A 
DCFH-DA  Dichloro-dihydro-fluorescein diacetate 
DHR123 Dihydrorhodamine 123  
DMSO  Dimethyl Sulfoxide 
DPBS  Dulbecco's Phosphate Buffered Saline 
DPBS-G DPBS + 5 mM glucose  
DPBS-GCM DPBS + 5 mM glucose + 1.2 mM CaCl2 + 1mM MgSO4 
EDTA  Ethylenediaminetetraacetic acid  
ELISA  Enzyme-linked immunosorbent assay 
FcR  Antibody Fc Receptor 
FI  Fluorescence Index 
FSC-A  Forward scatter – area of signal 
FSC-H  Forward scatter – height of signal 
IFNγ  Interferon gamma 
IgG  Immunoglobulin G 
IgM  Immunoglobulin M 
IS  Immune sera 
LPS  Lipopolysaccharide 
MSP   Major Surface Protein 
NIS  Non-immune sera 
OD  Optical Density 
OMP  Outer Membrane Protein 
OPA  Opsonophagocytic Activity 
PBMC  Peripheral Blood Mononuclear Cell 
PBS  Phosphate Buffered Saline 
PBS-T  PBS with 0.05 % Tween 20  
PCV  Packed Cell Volume 
PI  Propidium Iodide 
pNPP  p-nitrophenyl phosphate  
PRR  Pathogen Recognition Receptor 
RBC  Red blood cell 
RT  Room Temperature 
ROS  Reactive Oxygen Species 
SSC-A  Side scatter – height of signal 
SI  Stimulation Index 
TGF-beta Transforming Growth Factor beta 
TMB  Tetramethylbenzine 
UFMG1 Universidade Federal de Minas Gerais strain 1 
UFMG2 Universidade Federal de Minas Gerais strain 2 
USD  United States Dollars 
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